var docs;if (!docs) docs =[]; docs["35"]={"3503":"<p><b>Title</b> Herbs (Hypotensive Properties) / Herbs (Hypotensive Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Herbs (Hypotensive Properties) may enhance the adverse/toxic effect of other Herbs (Hypotensive Properties). Excessive blood pressure lowering may manifest. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for excessive decreases in blood pressure if herbs possessing hypotensive properties are used together with other herbs or drugs possessing a similar potential. Patients should be encouraged to disclose all herbal/natural products that they are using to their prescriber and pharmacist, and clinicians are encouraged to use caution when considering changes to therapy that may result in additional blood pressure lowering.</p>\n<div>\n <p><b>Herbs (Hypotensive Properties) Interacting Members</b> Black Cohosh, California Poppy, Coleus, Goldenseal, Hawthorn, Mistletoe, Periwinkle, QuiNINE, Shepherd's Purse</p>\n</div> \n<p><b>Discussion</b> Many herbal products have been shown to decrease blood pressure in some individuals. Concomitant use with other herbs or drugs that possess a similar pharmacologic potential may increase the risk of excessive blood pressure lowering. Relatively limited clinical data and large degrees of both inter- and intra-patient as well as inter- and intra-product variability complicate this issue further.<sup>1,2</sup><br><br>Patients should be encouraged to disclose all herbal/natural products that they are using to their prescriber and pharmacist, and clinicians are encouraged to use caution when considering changes to therapy that may result in additional blood pressure lowering.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Richard CL, Jurgens TM, “Effects of Natural Health Products on Blood Pressure,” <i>Ann Pharmacother</i>, 2005, 39(4):712-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15741425\">[PubMed 15741425]</a></p>\n<p>2. Ernst E, “Cardiovascular Adverse Effects of Herbal Medicines: A Systematic Review of the Recent Literature,” <i>Can J Cardiol</i>, 2003, 19(7):818-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12813616\">[PubMed 12813616]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3504":"<p><b>Title</b> Estrogen Derivatives / Herbs (Estrogenic Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Herbs (Estrogenic Properties) may enhance the adverse/toxic effect of Estrogen Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of increased estrogenic effects/toxicity if phytoestrogenic herbs and other estrogen derivatives are used concomitantly.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n <p><b>Herbs (Estrogenic Properties) Interacting Members</b> Alfalfa, Black Cohosh, Bloodroot, Hops, Kudzu, Licorice, Red Clover, Saw Palmetto, Soybean, Thyme, Wild Yam, Yucca</p>\n</div> \n<p><b>Discussion</b> Some herbs contain estrogenic compounds that can mimic the body's natural estrogen. Patients receiving estrogen therapy (eg, hormone replacement, contraceptive products) may experience signs/symptoms of estrogen overdose if used concomitant with such herbs. Note that ethinyl estradiol patches and vaginal rings introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zava DT, Dollbaum CM and Blen M, “Estrogen and Progestin Bioactivity of Foods, Herbs, and Spices,” <i>Proc Soc Exp Biol Med</i>, 1998, 217(3):369-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9492350\">[PubMed 9492350]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3505":"<p><b>Title</b> Progestins / Herbs (Progestogenic Properties)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Herbs (Progestogenic Properties) may enhance the adverse/toxic effect of Progestins. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of increased progestogenic effects/toxicity if phytoprogestogenic herbs and other progestins are used concomitantly.</p>\n<div>\n <p><b>Herbs (Progestogenic Properties) Interacting Members</b> Bloodroot, Chasteberry, Damiana, Oregano, Yucca</p>\n <p><b>Progestins Interacting Members</b> Chlormadinone, Cyproterone, Desogestrel, Dienogest, Drospirenone, Dydrogesterone, Ethynodiol Diacetate, Etonogestrel, Gestodene, HYDROXYprogesterone Caproate, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Megestrol, Norelgestromin, Norethindrone, Norgestimate, Norgestrel, Progesterone</p>\n</div> \n<p><b>Discussion</b> Some herbs contain progestogenic compounds that can mimic the body's natural progestins. Patients receiving progestin therapy (eg, hormone replacement, contraceptive products) may experience signs/symptoms of progestin overdose if used concomitant with such herbs. Note that many non-oral progestin-containing products (gels, vaginal rings, injectables, etc) introduce substantial circulating drug concentrations; therefore, caution with coadministration of interacting drugs is also warranted with these routes of administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zava DT, Dollbaum CM and Blen M, “Estrogen and Progestin Bioactivity of Foods, Herbs, and Spices,” <i>Proc Soc Exp Biol Med</i>, 1998, 217(3):369-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9492350\">[PubMed 9492350]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3506":"<p><b>Title</b> Didanosine / Tenofovir Disoproxil Fumarate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tenofovir Disoproxil Fumarate may diminish the therapeutic effect of Didanosine. Tenofovir Disoproxil Fumarate may increase the serum concentration of Didanosine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant treatment with tenofovir disoproxil fumarate and didanosine. Consider altering even existing, stable treatment to avoid this combination.</p> \n<p><b>Discussion</b> The AUC and maximum concentration of didanosine (400 mg/day, buffered formulation) were increased by 44% and 28%, respectively when coadministered with tenofovir disoproxil fumarate (300 mg/day).<sup>1</sup> Separating doses of didanosine and tenofovir by 2 hours may not change the outcome.<sup>2</sup> This effect may be caused by tenofovir inhibition of purine nucleoside phosphorylase (PNP), an enzyme involved in didanosine clearance.<sup>3</sup> Three cases of fatal lactic acidosis, possibly due, in part, to increased serum concentrations of didanosine caused by this interaction, have been reported.<sup>4,5,6</sup> All patients were stable on didanosine for several months prior to tenofovir initiation. The length of time between tenofovir initiation and the development of lactic acidosis in these cases ranges from one day to 17 months. Several cases of pancreatitis during concomitant didanosine and tenofovir administration have been reported.<sup>7,8</sup> An increased risk of hyperglycemia has also been reported.<sup>9</sup><br><br>In addition to the apparent didanosine-related toxicities, mounting evidence indicates that patients receiving the combination of didanosine and tenofovir disoproxil fumarate are at increased risk for negative immunologic effects (i.e., reductions in CD4 cell counts) and/or negative virologic effects.<sup>10,11,12,13,14</sup><br><br>In general, reduced doses of didanosine during concurrent tenofovir disoproxil fumarate administration are better tolerated and more effective than normal, full doses.<sup>15</sup> The manufacturers of didanosine and tenofovir recommend dosage reductions of didanosine if used in combination.<sup>1,16</sup> Specifically, they recommend a dose reduction to 200 mg (in patients less than 60 kg) or 250 mg (in patients greater than 60 kg), assuming the patient's calculated creatinine clearance is at least 60 mL/min.<sup>16</sup> However, rather than adjust dose as suggested in prescribing information, both the European Agency for the Evaluation of Medicinal Products (EMEA) and the U.S. Department of Health and Human Services have called for outright avoidance of this combination due to the high risk of adverse clinical outcomes.<sup>17,18</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Viread (tenofovir disoproxil fumarate). Foster City, CA: Gilead Sciences, Inc, July 2013.</p>\n<p>2. Gallant JE and Deresinski S, “Tenofovir Disoproxil Fumarate,” <i>Clin Infect Dis</i>, 2003, 37(7):944-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13130407\">[PubMed 13130407]</a></p>\n<p>3. Ray AS, Olson L, and Fridland A, “Role of Purine Nucleoside Phosphorylase in Interactions Between 2',3'-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir,” <i>Antimicrob Agents Chemother</i>, 2004, 48(4):1089-95. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15047506\">[PubMed 15047506]</a></p>\n<p>4. Murphy MD, O'Hearn M, and Chou S, “Fatal Lactic Acidosis and Acute Renal Failure After Addition of Tenofovir to an Antiretroviral Regimen Containing Didanosine,” <i>Clin Infect Dis</i>, 2003, 36(8):1082-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12684925\">[PubMed 12684925]</a></p>\n<p>5. Rivas P, Polo J, de Gorgolas M, et al, “Drug Points: Fatal Lactic Acidosis Associated with Tenofovir,” <i>BMJ</i>, 2003, 327(7417):711. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14512477\">[PubMed 14512477]</a></p>\n<p>6. Guo Y and Fung HB, “Fatal Lactic Acidosis Associated with Coadministration of Didanosine and Tenofovir Disoproxil Fumarate,” <i>Pharmacother</i>, 2004, 24(8):1089-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15338857\">[PubMed 15338857]</a></p>\n<p>7. Kirian MA, Higginson RT, and Fulco PP, “Acute Onset of Pancreatitis with Concomitant Use of Tenofovir and Didanosine,” <i>Ann Pharmacother</i>, 2004, 38(10):1660-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15340130\">[PubMed 15340130]</a></p>\n<p>8. Blanchard JN, Wohlfeiler M, Canas A, King K, et al, “Pancreatitis with Didanosine and Tenofovir Disoproxil Fumarate,” <i>Clin Infect Dis</i>, 2003, 37(5):e57-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12942419\">[PubMed 12942419]</a></p>\n<p>9. Garcia-Benayas T, Barrios A, Sanchez-Conde M, et al, “Higher Risk of Hyperglycemia in Patients Under Didanosine- and Tenofovir-Containing Regimens,” <i>12th Conference on Retroviruses and Opportunistic Infections</i>, February 22-25, 2005, Boston, MA, Abstract 829.</p>\n<p>10. Kakuda TN, Anderson PL, and Becker SL, “CD4 Cell Decline with Didanosine and Tenofovir and Failure of Triple Nucleoside/Nucleotide Regimens May Be Related,” <i>AIDS</i>. 2004, 18(18):2442-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15622326\">[PubMed 15622326]</a></p>\n<p>11. Perez-Elias MJ, Moreno S, Gutierrez C, et al, “High Virological Failure Rate in HIV Patients After Switching to a Regimen With Two Nucleoside Reverse Transcriptase Inhibitors Plus Tenofovir,” <i>AIDS</i>, 2005, 19(7):695-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15821395\">[PubMed 15821395]</a></p>\n<p>12. Barrios A, Rendon A, Negredo E, et al, “Paradoxical CD4+ T-Cell Decline in HIV-Infected Patients with Complete Virus Suppression Taking Tenofovir and Didanosine,” <i>AIDS</i>, 2005, 19(6):569-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15802975\">[PubMed 15802975]</a></p>\n<p>13. Podzamczer D, Ferrer E, Gatell JM, et al, “Early Virological Failure with a Combination of Tenofovir, Didanosine and Efavirenz,” <i>Antivir Ther</i>, 2005, 10(1):171-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15751775\">[PubMed 15751775]</a></p>\n<p>14. Negredo E, Molto J, Burger D, et al, “Unexpected CD4 Cell Count Decline in Patients Receiving Didanosine and Tenofovir-Based Regimens Despite Undetectable Viral Load,” <i>AIDS</i>, 2004, 18(3):459-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15090798\">[PubMed 15090798]</a></p>\n<p>15. Tung M-Y, Mandalia S, Bower M, et al, “The Durability of Virological Success of Tenofovir and Didanosine Dosed at Either 400 or 250 mg Once Daily,” <i>HIV Med</i>, 2005, 6(3):151-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15876280\">[PubMed 15876280]</a></p>\n<p>16. Prescribing information. Videx (didanosine). Princeton, NJ: Bristol-Myers Squibb Company, 2004.</p>\n<p>17. EMEA Public Statement, “Efficacy and Safety Concerns Regarding the Co-Administration of Tenofovir Disoproxil Fumarate (TDF, Viread) and Didanosine (ddI, Videx),” European Agency for the Evaluation of Medicinal Products, London, March 3, 2005. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500014809.pdf. Accessed 3/28/2011.</p>\n<p>18. Panel on Antiretroviral Guidelines for Adults and Adolescents, “Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents,” Department of Health and Human Services, 2011, 1-166. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 3/28/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3510":"<p><b>Title</b> Protease Inhibitors / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Macrolide Antibiotics may decrease the metabolism of Protease Inhibitors. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required. Information on the interaction between clarithromycin and protease inhibitors is found in a separate monograph.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Erythromycin (Systemic), Telithromycin<br><b>Exceptions</b> Azithromycin (Systemic), Clarithromycin, Fidaxomicin, Roxithromycin, Spiramycin</p>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir*, Tipranavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of saquinavir (1200 mg 3 times/day) was increased 99% in 33 HIV-infected patients when coadministered with erythromycin (250 mg 3 times/day).<sup>1</sup> Erythromycin likely inhibits the CYP metabolism of the protease inhibitor. The clinical effect of this interaction appears minimal. Telithromycin, a ketolide antibiotic, might affect protease inhibitors in a similar fashion.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Grub S, Bryson H, Goggin T, et al, “The Interaction of Saquinavir (Soft Gelatin Capsule) With Ketoconazole, Erythromycin, and Rifampicin: Comparison of the Effect in Healthy Volunteers and in HIV-Infected Patients,” <i>Eur J Clin Pharmacol</i>, 2001, 57(2):115-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11417442\">[PubMed 11417442]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3511":"<p><b>Title</b> Antiarrhythmic Agents (Class Ia) / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Amiodarone may enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia). <b>Severity</b> Major <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid the combined use or amiodarone with class IA antiarrhythmic agents whenever possible. Concomitant use is expected to substantially increase the risk for serious toxicities, including the development of torsades de pointes or other significant ventricular tachyarrhythmias. Patients with other risk factors present (e.g., older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations), would be at an even higher risk for these potentially life-threatening toxicities. Although product information in some places (e.g., in the United Kingdom) lists the combined use of amiodarone with class IA antiarrhythmics as contraindicated, amiodarone U.S. prescribing information suggests that concomitant use could be considered under some circumstances. If used monitor patients closely for evidence of QTc prolongation or arrhythmia. Reduce quinidine or procainamide doses by one third.</p>\n<div>\n <p><b>Antiarrhythmic Agents (Class Ia) Interacting Members</b> Ajmaline, Disopyramide*, Procainamide*, QuiNIDine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Data from 5 patients demonstrated a prolonged QT interval during concomitant therapy with amiodarone and disopyramide and the subsequent development of torsades de pointes.<sup>1</sup> Serum quinidine concentrations increased an average of 32% in 11 patients after approximately one week of concomitant amiodarone administration (600 mg twice daily x 5-7 days, then 600 mg/day).<sup>2</sup> Signs and symptoms of quinidine toxicity (GI, hypotension) were noted in some patients. The quinidine dosage was reduced by approximately one-third in most patients in order to re-establish acceptable quinidine serum concentrations. The same report describes similar effects on procainamide in response to concurrent amiodarone.<sup>2</sup> Another report describes a doubling of serum quinidine concentration in a normal subject within 3 days of initiating amiodarone (600 mg/day).<sup>3</sup> The QT interval was noted to increase from 1.2 msec (quinidine alone) to 1.4 msec (quinidine + amiodarone). In a study of 8 patients, procainamide clearance decreased an average of 23% following initiation of amiodarone.<sup>4</sup> Further, a comparison of amiodarone alone (n=20) to amiodarone plus either procainamide (n=13) or quinidine (n=4) demonstrated no additional improvements with combination therapy and a high rate of adverse effects (40% of patients) in a study of patients who had experienced ventricular tachyarrhythmias induced by amiodarone therapy.<sup>5</sup><br><br>It is likely that several mechanisms contribute to these observed interactions, including an additive QTc-prolonging effect of the individual agents and an increase in antiarrhythmic drug concentrations related to the ability of amiodarone to inhibit the CYP3A4 and possibly CYP2C8/9 metabolism of quinidine, the CYP2D6 metabolism of procainamide, and possibly the CYP3A4-mediated metabolism of disopyramide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Keren A, Tzivoni D, Gavish D, et al, “Etiology, Warning Signs and Therapy of Torsade de Pointes,” <i>Circulation</i>, 1981, 64:1167-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7296791\">[PubMed 7296791]</a></p>\n<p>2. Saal AK, Werner JA, Greene HL, et al, “Effect of Amiodarone on Serum Quinidine and Procainamide Levels,” <i>Am J Cardiol</i>, 1984, 53:1265-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6711425\">[PubMed 6711425]</a></p>\n<p>3. Tartini R, Kappenberger L, Steinbrunn W, et al, “Dangerous Interaction Between Amiodarone and Quinidine,” <i>Lancet</i>, 1982, i:1327-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6123639\">[PubMed 6123639]</a></p>\n<p>4. Windle J, Prystowsky EN, Miles WM, et al, “Pharmacokinetic and Electrophysiologic Interactions of Amiodarone and Procainamide,” <i>Clin Pharmacol Ther</i>, 1987, 41:603-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3581646\">[PubMed 3581646]</a></p>\n<p>5. Marchlinski FE, Buxton AE, Miller JM, et al, “Amiodarone Versus Amiodarone and a Type IA Agent for Treatment of Patients with Rapid Ventricular Tachycardia,” <i>Circulation</i>, 1986, 74(5):1037-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3769163\">[PubMed 3769163]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3512":"<p><b>Title</b> Flecainide / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Amiodarone may enhance the QTc-prolonging effect of Flecainide. Amiodarone may increase the serum concentration of Flecainide. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Decrease flecainide dose by 50% in the presence of amiodarone. Monitor for adverse effects of flecainide and consider monitoring for elevated serum concentrations during concomitant therapy.</p> \n<p><b>Discussion</b> Case reports describe development of substantial QRS complex widening<sup>1</sup> and torsades de pointes<sup>2</sup> in patients treated concomitantly with amiodarone and flecainide. In a clinical study, dose-adjusted trough plasma flecainide concentrations were increased approximately 50% in 8 patients following the addition of amiodarone (1,200 mg daily for 10-14 days, then 600 mg daily).<sup>3</sup> The flecainide dosage was decreased by approximately one-third to one-half in order to maintain acceptable serum concentrations. A later study successfully used a dose reduction of approximately one-third in the management of infants with tacchyarrhythmias,<sup>4</sup> and a separate pharmacokinetic study suggested dose reductions of up to 50% in patients with heart failure or in combination with amiodarone.<sup>5</sup><br><br>The likely primary mechanism of this interaction is amiodarone inhibition of flecainide via CYP2D6. Concomitant therapy would be expected to result in decreased flecainide metabolism and increased plasma concentrations. In one study, CYP2D6 poor metabolizers had a trend toward higher flecainide concentrations and a greater increase in those concentrations with amiodarone, but the trend did not reach statistical significance.<sup>6</sup> Prescribing information for flecainide recommends a dose reduction of 50% in the presence of amiodarone.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kantoch MJ, “Combination of Amiodarone and Flecainide,” <i>Am J Cardiol</i>, 1995, 75(12):862. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7717302\">[PubMed 7717302]</a></p>\n<p>2. Andrivet P, Beaslay V and Canh VD, “Torsades de Pointe with Flecainide-Amiodarone Therapy,” <i>Intensive Care Med</i>, 1990, 16(5):342-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2120306\">[PubMed 2120306]</a></p>\n<p>3. Shea P, Lal R, Kim SS, et al, “Flecainide and Amiodarone Interaction,” <i>J Am Coll Cardiol</i>, 1986, 7:1127-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3958371\">[PubMed 3958371]</a></p>\n<p>4. Fenrich AL Jr, Perry JC and Friedman RA, “Flecainide and Amiodarone: Combined Therapy for Refractory Tachyarrhythmias in Infancy,” <i>J Am Coll Cardiol</i>, 1995, 25(5):1195-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7897134\">[PubMed 7897134]</a></p>\n<p>5. Leclercq JF, Denjoy I, Mentre F, et al, “Flecainide Acetate Dose-Concentration Relationship in Cardiac Arrhythmias: Influence of Heart Failure and Amiodarone,” <i>Cardiovasc Drugs Ther</i>, 1990, 4(4):1161-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2128031\">[PubMed 2128031]</a></p>\n<p>6. Funck-Brentano C, Becquemont L, Kroemer HK, et al, “Variable Disposition Kinetics and Electrocardiographic Effects of Flecainide During Repeated Doses in Humans: Contribution of Genetic Factors, Dose-Dependent Clearance, and Interaction with Amiodarone,” <i>Clin Pharmacol Ther</i>, 1994, 55:256-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8143391\">[PubMed 8143391]</a></p>\n<p>7. Prescribing information. Tambocor (flecainide). Northridge, CA: 3M Pharmaceuticals, June 1998.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3514":"<p><b>Title</b> Neuromuscular-Blocking Agents / Lincosamide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for prolonged/enhanced neuromuscular blockade during concomitant use of these agents.</p>\n<div>\n <p><b>Lincosamide Antibiotics Interacting Members</b> Clindamycin (Systemic)*, Lincomycin*</p>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium*, Rocuronium, Succinylcholine*, Vecuronium</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Several case reports describe increased duration and/or intensity of pharmacologic effects of neuromuscular blocking agents with concomitant administration of lincosamide antibiotics.<sup>1,2,3,4,5</sup> <br><br>This interaction is likely the result of combined neuromuscular blocking activities of the individual agents. Clindamycin and lincomycin may exhibit neuromuscular blocking activity independent of coadministration of other neuromuscular blocking agents.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sloan PA, Rasul M. Prolongation of rapacuronium neuromuscular blockade by clindamycin and magnesium. <i>Anesth Analg</i>. 2002;94(1):123-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11772813\">[PubMed 11772813]</a></p>\n<p>2. Fogdall RP, Miller RD. Prolongation of a pancuronium-induced neuromuscular blockade by clindamycin. <i>Anesthesiology</i>. 1974;41(4):407-408. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4415332\">[PubMed 4415332]</a></p>\n<p>3. Booij LH, Miller RD, Crul JF. Neostigmine and 4-aminopyridine antagonism of lincomycin-pancuronium neuromuscular blockade in man. <i>Anesth Analg</i>. 1978;57(3):316-321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=566050\">[PubMed 566050]</a></p>\n<p>4. Avery D, Finn R. Succinylcholine-prolonged apnea associated with clindamycin and abnormal liver function tests. <i>Dis Nerv Syst</i>. 1977;38(6):473-475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=862507\">[PubMed 862507]</a></p>\n<p>5. Jedeikin R, Dolgunski E, Kaplan R, Hoffman S. Prolongation of neuromuscular blocking effect of vecuronium by antibiotics. <i>Anaesthesia</i>. 1987;42(8):858-860. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2889390\">[PubMed 2889390]</a></p>\n<p>6. <i>Cleocin Phosphate</i> (clindamycin phosphate) [prescribing information]. New York, NY: Pfizer Inc; April 2008.</p>\n<p>7. <i>Lincocin</i> (lincomycin) [prescribing information]. Kalamazoo, MI: Pharmacia and Upjohn Company; June 2007.</p>\n<p>8. al Ahdal O and Bevan DR. Clindamycin-induced neuromuscular blockade. <i>Can J Anaesth</i>. 1995;42(7):614-617. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7553999\">[PubMed 7553999]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3517":"<p><b>Title</b> Vitamin K Antagonists / Methylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methylphenidate may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Increase monitoring of clinical response to vitamin K antagonists when starting/stopping or changing the dose of concurrent methylphenidate. Monitor for increased anticoagulant response with increased methylphenidate doses or initiation of therapy, and monitor for decreased anticoagulant with reduced methylphenidate doses or discontinuation.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The half-life of the coumarin derivative, ethyl biscoumacetate, was increased approximately 2-fold in 4 healthy subjects following the administration of a 3- to 5-day course of methylphenidate.<sup>1</sup> A subsequent double-blind study in 12 healthy volunteers failed to confirm these results.<sup>2</sup><br><br>The prescribing information for dexmethylphenidate notes that human studies with racemic methylphenidate have suggested that methylphenidate may inhibit the metabolism of coumarin anticoagulants, though no specific data about such an interaction is provided.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Garrettson LK, Perel JM, and Dayton PG, “Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate,” <i>JAMA</i>, 1969, 207:2053. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5818377\">[PubMed 5818377]</a></p>\n<p>2. Hague DE, Smith ME, Ryan JR, et al, “The Interaction of Methylphenidate and Prolintane With Ethyl Biscoumacetate Metabolism,” Fed Proc, 1971, 30:336. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4396632\">[PubMed 4396632]</a> </p>\n<p>3. Prescribing information. Ritalin (methylphenidate). East Hanover, NJ: Novartis Pharmaceuticals Corporation. April 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3518":"<p><b>Title</b> Tricyclic Antidepressants / Methylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methylphenidate may enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxicity of tricyclic antidepressants if methylphenidate is initiated/dose increased.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine*, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports have described patients who have experienced several-fold increases in serum tricyclic antidepressant (TCA) concentrations following the addition of methylphenidate.<sup>1,2</sup> None of these reported patients experienced negative clinical effects. In contrast, another case report described two patients who each experienced cognitive and mood disturbances attributed to an interaction between methylphenidate and the TCA desipramine.<sup>3</sup><br><br>The results of systematic evaluations of this possible interaction have been mixed. One double-blind crossover study evaluating methylphenidate and desipramine alone and in combination noted significantly more adverse effects (most commonly tremor, dry mouth, and nausea) with use of the combination than with either agent alone.<sup>4</sup> Another study, a retrospective review of 142 children who were receiving desipramine alone or with a stimulant (methylphenidate or dexedrine), reported no significant differences in desipramine pharmacokinetics with concurrent use of methylphenidate.<sup>5</sup> Similarly, a case report describes one patient in whom desipramine concentrations were unchanged by the addition of methylphenidate (and in whom the combination resulted in successful treatment of the patient's depression).<sup>6</sup><br><br>The mechanism of this purported interaction is uncertain. An initial report hypothesized that methylphenidate is inhibited the hepatic metabolism of the TCAs,<sup>2</sup> but the data in support of no such pharmacokinetic interaction are at least as strong as the data in favor of such an interaction.<sup>1,2,5,6</sup> Further calling into question the potential for such a metabolism-related interaction is the apparent lack of effect of methylphenidate on CYP2D6, which is the enzyme primarily responsible for the metabolism of nortriptyline and desipramine (and is also involved in the metabolism of the other TCAs).<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cooper TN and Simpson GM, “Concomitant Imipramine and Methylphenidate Administration: A Case Report,” <i>Am J Psychiatry</i>, 1973, 130:721. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4701968\">[PubMed 4701968]</a></p>\n<p>2. Wharton RN, Perel JM, Dayton PG, et al, “A Potential Use for the Interaction of Methylphenidate With Tricyclic Antidepressants,” <i>Am J Psychiatry</i>, 1971, 127:1619. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4998422\">[PubMed 4998422]</a></p>\n<p>3. Grob CS, Coyle JT, “Suspected Adverse Methylphenidate-Imipramine Interactions in Children,” <i>J Dev Behav Pediatr</i>, 1986, 7(4):265-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3018047\">[PubMed 3018047]</a></p>\n<p>4. Pataki CS, Carlson GA, Kelly KL, et al, “Side Effects of Methylphenidate and Desipramine Alone and in Combination in Children,” <i>J Am Acad Child Adolesc Psychiatry</i>, 1993, 32(5):1065-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8407753\">[PubMed 8407753]</a></p>\n<p>5. Cohen LG, Prince J, Biederman J, et al, “Absence of Effect of Stimulants on the Phamacokinetics of Desipramine in Children,” <i>Pharmacotherapy</i>, 1999, 19(6):746-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10391421\">[PubMed 10391421]</a></p>\n<p>6. Drimmer EJ, Gitlin MJ, Gwirtsman HE, “Desipramine and Methylphenidate Combination Treatment for Depression: Case Report,” <i>Am J Psychiatry</i>, 1983, 140(2):241-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6849446\">[PubMed 6849446]</a></p>\n<p>7. Ciccone PE, Ramabadran K, Jessen LM, “Potential Interactions of Methylphenidate and Atomoxetine with Dextromethorphan,” <i>J Am Pharm Assoc (2003)</i>, 2006, 46(4):472-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16913391\">[PubMed 16913391]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3519":"<p><b>Title</b> Phenytoin / Methylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methylphenidate may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Prescribing information for methylphenidate states that human pharmacologic studies have been conducted showing that methylphenidate may inhibit the metabolism of anticonvulsants including phenytoin.<sup>1</sup> Cases of phenytoin intoxication following methylphenidate initiation have been reported.<sup>2,3</sup> However, a number of other case reports have been published where this effect was not detected.<sup>4,5</sup><br><br>The mechanism of this potential interaction is unclear, as are the frequency of occurrence and potential clinical significance.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ritalin (methylphenidate). East Hanover, New Jersey: Novartis Pharmaceuticals Corporation, April 2007.</p>\n<p>2. Garrettson KJ, Perel JM, and Dayton PG, “Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate,” <i>JAMA</i>, 1969, 207:2053-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5818377\">[PubMed 5818377]</a></p>\n<p>3. Ghofrani M, “Possible Phenytoin-Methylphenidate Interaction,” <i>Dev Med Child Neurol</i>, 1988, 30(2):267-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3133263\">[PubMed 3133263]</a></p>\n<p>4. Mirkin BL and Wright F, “ Drug Interactions: Effects of Methylphenidate on the Disposition of Diphenylhydantoin in Man,” <i>Neurology</i>, 1971, 21:1123-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5166217\">[PubMed 5166217]</a></p>\n<p>5. Kupferberg HJ, Jeffery W, and Hunninghake DB, “Effect of Methylphenidate on Plasma Anticonvulsant Levels,” <i>Clin Pharmacol Ther</i>, 1972, 13:201-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4552820\">[PubMed 4552820]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3520":"<p><b>Title</b> Methylphenidate / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Methylphenidate. <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Methylphenidate use is contraindicated during and within 14 days of discontinuation of a monoamine oxidase inhibitor.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> Monoamine oxidase inhibitors (nonselective) cause an accumulation of norepinephrine within adrenergic neurons. Of particular importance are the neurons in the sympathetic system that innervate arterial blood vessels. Under such circumstances, the administration of an indirect-acting alpha-/beta-agonist (or any other indirect-acting sympathomimetic) will cause the release of the stored, excess norepinephrine, and a subsequent exaggerated constriction of blood vessels - thus an exaggerated increase in blood pressure.<sup>1,2,3,4,5,6,7</sup> The hypertensive reactions can occur within minutes of sympathomimetic administration. Fatalities have occurred. The effect of selective MAOIs on alpha/beta agonist toxicity is likely less than with nonselective products, however, one report describes a three to fourfold increase in the pressor effects of ephedrine in subjects receiving moclobemide.<sup>8,9</sup> Linezolid is reported to cause minimal (but statistically significant) changes in serum concentrations of the alpha-/beta-agonists, with small increases in blood pressure noted in most subjects.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ritalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2002.</p>\n<p>2. Elis J, Laurence DR, Mattie H, et al, “Modification by Monoamine Oxidase Inhibitors of the Effects of Some Sympathomimetics on Blood Pressure,” <i>Br Med J</i>, 1967, 2:75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6020852\">[PubMed 6020852]</a></p>\n<p>3. Low-Beer GA and Tidmarsh D, “Collapse after Parstelin,” <i>Br Med J</i>, 1963, 2:683. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14056938\">[PubMed 14056938]</a> </p>\n<p>4. Wright SP, “Hazards With Monoamine Oxidase Inhibitors: A Persistent Problem,” <i>Lancet</i>, 1978, i:284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=74715\">[PubMed 74715]</a></p>\n<p>5. Harrison WM, McGrath PJ, Stewart JW, et al, “MAOIs and Hypertensive Crises: The Role of OTC Drugs,” <i>J Clin Psychiatry</i>, 1989, 50:64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2464583\">[PubMed 2464583]</a></p>\n<p>6. Sherman M, Hauser GC, and Glover BH, “Toxic Reactions to Tranylcypromine,” <i>Am J Psychiatry</i>, 1964, 120:1019. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14138839\">[PubMed 14138839]</a></p>\n<p>7. Jenkins LC and Graves HB, “Potential Hazards of Psychoactive Drugs in Association With Anaesthesia,” <i>Can Anaesth Soc J</i>, 1965, 12:121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14311657\">[PubMed 14311657]</a></p>\n<p>8. Dingemanse J, “An Update of Recent Moclobemide Interaction Data,” <i>Int Clin Psychopharmacol</i>, 1993, 7:167-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8468439\">[PubMed 8468439]</a></p>\n<p>9. Dingemanse J, Guentert T, Gieschke R, et al, “Modification of the Cardiovascular Effects of Ephedrine by the Reversible Monoamine Oxidase A-Inhibitor Moclobemide,” <i>J Cardiovasc Pharmacol</i>, 1996, 28:856-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8961085\">[PubMed 8961085]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3521":"<p><b>Title</b> Vitamin K Antagonists / Dexmethylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexmethylphenidate may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Increase monitoring of clinical response to vitamin K antagonists when starting/stopping or changing the dose of concurrent dexmethylphenidate. Monitor for increased anticoagulant response with increased dexmethylphenidate doses or initiation of therapy, and monitor for decreased anticoagulant with reduced dexmethylphenidate doses or discontinuation.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> The half-life of the coumarin derivative, ethyl biscoumacetate, was increased approximately 2-fold in 4 healthy subjects following the administration of a 3- to 5-day course of methylphenidate.<sup>1</sup> A subsequent double-blind study in 12 healthy volunteers failed to confirm these results.<sup>2</sup><br><br>The prescribing information for dexmethylphenidate notes that human studies with racemic methylphenidate have suggested that methylphenidate may inhibit the metabolism of coumarin anticoagulants, though no specific data about such an interaction is provided.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Garrettson LK, Perel JM, and Dayton PG, “Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate,” <i>JAMA</i>, 1969, 207:2053. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5818377\">[PubMed 5818377]</a></p>\n<p>2. Hague DE, Smith ME, Ryan JR, et al, “The interaction of Methylphenidate and Prolintane With Ethyl Biscoumacetate Metabolism,” <i>Fed Proc</i>, 1971, 30:336.</p>\n<p>3. Prescribing information. Focalin (dexmethylphenidate). East Hanover, NJ: Novartis Pharmaceuticals Corporation. April 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3522":"<p><b>Title</b> Tricyclic Antidepressants / Dexmethylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexmethylphenidate may enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxicity of tricyclic antidepressants if dexmethylphenidate is initiated/dose increased.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> Case reports have described patients who have experienced several-fold increases in serum tricyclic antidepressant (TCA) concentrations following the addition of methylphenidate.<sup>1,2</sup> None of these reported patients experienced negative clinical effects. In contrast, another case report described two patients who each experienced cognitive and mood disturbances attributed to an interaction between methylphenidate and the TCA desipramine.<sup>3</sup><br><br>The results of systematic evaluations of this possible interaction have been mixed. One double-blind crossover study evaluating methylphenidate and desipramine alone and in combination noted significantly more adverse effects (most commonly tremor, dry mouth, and nausea) with use of the combination than with either agent alone.<sup>4</sup> Another study, a retrospective review of 142 children who were receiving desipramine alone or with a stimulant (methylphenidate or dexedrine), reported no significant differences in desipramine pharmacokinetics with concurrent use of methylphenidate.<sup>5</sup> Similarly, a case report describes one patient in whom desipramine concentrations were unchanged by the addition of methylphenidate (and in whom the combination resulted in successful treatment of the patient's depression).<sup>6</sup><br><br>The mechanism of this purported interaction is uncertain. An initial report hypothesized that methylphenidate is inhibited the hepatic metabolism of the TCAs,<sup>2</sup> but the data in support of no such pharmacokinetic interaction are at least as strong as the data in favor of such an interaction.<sup>1,2,5,6</sup> Further calling into question the potential for such a metabolism-related interaction is the apparent lack of effect of methylphenidate on CYP2D6, which is the enzyme primarily responsible for the metabolism of nortriptyline and desipramine (and is also involved in the metabolism of the other TCAs).<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cooper TN and Simpson GM, “Concomitant Imipramine and Methylphenidate Administration: A Case Report,” <i>Am J Psychiatry</i>, 1973, 130:721. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4701968\">[PubMed 4701968]</a></p>\n<p>2. Wharton RN, Perel JM, Dayton PG, et al, “A Potential Use for the Interaction of Methylphenidate With Tricyclic Antidepressants,” <i>Am J Psychiatry</i>, 1971, 127:1619. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4998422\">[PubMed 4998422]</a></p>\n<p>3. Grob CS, Coyle JT, “Suspected Adverse Methylphenidate-Imipramine Interactions in Children,” <i>J Dev Behav Pediatr</i>, 1986, 7(4):265-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3018047\">[PubMed 3018047]</a></p>\n<p>4. Pataki CS, Carlson GA, Kelly KL, et al, “Side Effects of Methylphenidate and Desipramine Alone and in Combination in Children,” <i>J Am Acad Child Adolesc Psychiatry</i>, 1993, 32(5):1065-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8407753\">[PubMed 8407753]</a></p>\n<p>5. Cohen LG, Prince J, Biederman J, et al, “Absence of Effect of Stimulants on the Phamacokinetics of Desipramine in Children,” <i>Pharmacotherapy</i>, 1999, 19(6):746-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10391421\">[PubMed 10391421]</a></p>\n<p>6. Drimmer EJ, Gitlin MJ, Gwirtsman HE, “Desipramine and Methylphenidate Combination Treatment for Depression: Case Report,” <i>Am J Psychiatry</i>, 1983, 140(2):241-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6849446\">[PubMed 6849446]</a></p>\n<p>7. Ciccone PE, Ramabadran K, Jessen LM, “Potential Interactions of Methylphenidate and Atomoxetine with Dextromethorphan,” <i>J Am Pharm Assoc (2003)</i>, 2006, 46(4):472-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16913391\">[PubMed 16913391]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3523":"<p><b>Title</b> Dexmethylphenidate / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Dexmethylphenidate. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of dexmethylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> Two case reports describe challenges in achieving therapeutic serum concentrations (and clinical efficacy) of methylphenidate in pediatric patients also receiving carbamazepine.<sup>1,2</sup> In one case, the methylphenidate dose was increased to 30 mg every 4 hours without any benefit, and in the other a doubling of the methylphenidate dose (following the addition of carbamazepine) was needed to maintain efficacy. The mechanism of this interaction is unknown. It may be related to increased metabolism of methylphenidate (primarily via de-esterification) stimulated by carbamazepine, which is a well-known inducer of several different drug metabolizing enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Behar D, Schaller J, Spreat S, “Extreme Reduction of Methylphenidate Levels by Carbamazepine,” <i>J Am Acad Child Adolesc Psychiatry</i>, 1998, 37:1128-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9808919\">[PubMed 9808919]</a></p>\n<p>2. Schaller JL, Behar D, “Carbamazepine and Methylphenidate in ADHD,” <i>J Am Acad Child Adolesc Psychiatry</i>, 1999, 38:112-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9951206\">[PubMed 9951206]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3524":"<p><b>Title</b> Dexmethylphenidate / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Dexmethylphenidate. <b>Severity</b> Major <b>Onset</b> Immediate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use of indirect-acting sympathomimetics (eg, dexmethylphenidate) and monoamine oxidase inhibitors should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents. In general, furazolidone, linezolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Caution is still advised, particularly monitoring for increased blood pressure. Selegiline administered in high oral dosages (eg, &gt;10 mg daily of tablet/capsule; &gt; 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tranylcypromine<br><b>Exception</b> Tedizolid</p>\n</div> \n<p><b>Discussion</b> Monoamine oxidase inhibitors (nonselective) cause an accumulation of norepinephrine within adrenergic neurons. Of particular importance are the neurons in the sympathetic system that innervate arterial blood vessels. Under such circumstances, the administration of an indirect-acting alpha-/beta-agonist (or any other indirect-acting sympathomimetic) will cause the release of the stored, excess norepinephrine, and a subsequent exaggerated constriction of blood vessels - thus an exaggerated increase in blood pressure.<sup>1,2,3,4,5,6</sup> The hypertensive reactions can occur within minutes of sympathomimetic administration. Fatalities have occurred. The effect of selective MAOIs on alpha-/beta-agonist toxicity is likely less than with nonselective products; however, one report describes a three- to fourfold increase in the pressor effects of ephedrine in subjects receiving moclobemide.<sup>7,8</sup> Linezolid is reported to cause minimal (but statistically significant) changes in serum concentrations of the alpha/beta agonists, with small increases in blood pressure noted in most subjects.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Jenkins LC and Graves HB, “Potential Hazards of Psychoactive Drugs in Association With Anaesthesia,” <i>Can Anaesth Soc J</i>, 1965, 12:121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14311657\">[PubMed 14311657]</a></p>\n<p>2. Elis J, Laurence DR, Mattie H, et al, “Modification by Monoamine Oxidase Inhibitors of the Effects of Some Sympathomimetics on Blood Pressure,” <i>Br Med J</i>, 1967, 2:75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6020852\">[PubMed 6020852]</a></p>\n<p>3. Low-Beer GA and Tidmarsh D, “Collapse After Parstelin,” <i>Br Med J</i>, 1963, 2:683.</p>\n<p>4. Wright SP, “Hazards with Monoamine Oxidase Inhibitors: A Persistent Problem,” <i>Lancet</i>, 1978, i:284. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=74715\">[PubMed 74715]</a></p>\n<p>5. Harrison WM, McGrath PJ, Stewart JW, et al, “MAOIs and Hypertensive Crises: The Role of OTC Drugs,” <i>J Clin Psychiatry</i>, 1989, 50:64-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2464583\">[PubMed 2464583]</a></p>\n<p>6. Sherman M, Hauser GC, and Glover BH, “Toxic Reactions to Tranylcypromine,” <i>Am J Psychiatry</i>, 1964, 120:1019. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14138839\">[PubMed 14138839]</a></p>\n<p>7. Dingemanse J, “An Update of Recent Moclobemide Interaction Data,” <i>Int Clin Psychopharmacol</i>, 1993, 7:167-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8468439\">[PubMed 8468439]</a></p>\n<p>8. Dingemanse J, Guentert T, Gieschke R, et al, “Modification of the Cardiovascular Effects of Ephedrine by the Reversible Monoamine Oxidase A-Inhibitor Moclobemide,” <i>J Cardiovasc Pharmacol</i>, 1996, 28:856-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8961085\">[PubMed 8961085]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3525":"<p><b>Title</b> Phenytoin / Dexmethylphenidate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexmethylphenidate may increase the serum concentration of Phenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum concentrations/toxicity of phenytoin if dexmethylphenidate is initiated/dose increased. Dosage adjustments may be required.</p> \n<p><b>Discussion</b> Prescribing information for dexmethylphenidate states that human pharmacologic studies have been conducted showing that methylphenidate may inhibit the metabolism of anticonvulsants including phenytoin.<sup>1</sup> Case reports of phenytoin intoxication following methylphenidate initiation have been reported.<sup>2,3</sup> However, a number of other case reports have been published where this effect was not detected.<sup>4,5</sup><br><br>The mechanism of this potential interaction is unclear, as are the frequency of occurrence and potential clinical significance. Methylphenidate isomer studies have not been conducted to elucidate the relative contributions of the d-threo (dexmethylphenidate) and l-threo enantiomers.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Focalin (dexmethylphenidate hydrochloride). East Hanover, New Jersey: Novartis Pharmaceuticals Corporation, April 2007.</p>\n<p>2. Garrettson KJ, Perel JM, and Dayton PG, “Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate,” <i>JAMA</i>, 1969, 207:2053-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5818377\">[PubMed 5818377]</a></p>\n<p>3. Ghofrani M, “Possible Phenytoin-Methylphenidate Interaction,” <i>Dev Med Child Neurol</i>, 1988, 30(2):267-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3133263\">[PubMed 3133263]</a></p>\n<p>4. Mirkin BL and Wright F, “ Drug Interactions: Effects of Methylphenidate on the Disposition of Diphenylhydantoin in Man,” <i>Neurology</i>, 1971, 21:1123-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5166217\">[PubMed 5166217]</a></p>\n<p>5. Kupferberg HJ, Jeffery W, and Hunninghake DB, “Effect of Methylphenidate on Plasma Anticonvulsant Levels,” <i>Clin Pharmacol Ther</i>, 1972, 13:201-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4552820\">[PubMed 4552820]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3526":"<p><b>Title</b> Methadone / Reverse Transcriptase Inhibitors (Non-Nucleoside)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the metabolism of Methadone. <b>Severity</b> Moderate <b>Onset</b> Rapid <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased serum concentrations of methadone (and associated withdrawal symptoms) if a non-nucleoside reverse transcriptase inhibitor is initiated/dose increased, or increased serum concentrations/effects if such an antiretroviral agent is discontinued/dose decreased. Methadone dosage adjustments will likely be required with efavirenz and nevirapine, and may be necessary with rilpivirine as well. This specific interaction appears limited to efavirenz, nevirapine, and rilpivirine (i.e., not delavirdine or etravirine).</p>\n<div>\n <p><b>Reverse Transcriptase Inhibitors (Non-Nucleoside) Interacting Members</b> Efavirenz*, Nevirapine*, Rilpivirine<br><b>Exceptions</b> Delavirdine, Etravirine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The average AUC of methadone was reduced by 57% in 11 therapy-stable patients when coadministered with efavirenz.<sup>1</sup> The maximum serum concentration (Cmax) was decreased an average of 48%, and methadone dosages required a mean increase of 22% in order to maintain effective therapy. A similar experience has been reported by these authors with nevirapine.<sup>2</sup> Similarly, methadone AUC decreased 41% after initiation of nevirapine therapy in a study of 20 patients.<sup>3</sup> Another study of 14 patients also found decreased concentrations of both S- and R-methadone (by 19-93%), with a greater decline for S-methadone, resulting in an increased R-/S-methadone ratio.<sup>4</sup> In a clinical study summarized in rilpivirine prescribing information, coadministration of rilpivirine (25 mg daily) with methadone (60-100 mg daily) decreased the maximum concentration, minimum concentration, and AUC of R-methadone (by 14%, 22%, and 16%, respectively) and S-methadone (by 13%, 21%, and 16%, respectively).<sup>5</sup> <br><br>The likely mechanism of this interaction is efavirenz- and nevirapine-mediated induction of methadone metabolism. Methadone is metabolized by several enzymes, including CYP2B6 and CYP3A4, and efavirenz and nevirapine are reported inducers of these enzymes. The potential for CYP induction by rilpivirine has not been characterized.<br><br>Of note, etravirine and delaviridine are not expected to interact similarly with methadone. An open label trial in HIV-negative patients (n=16) on stable methadone maintenance therapy showed no change in the ratio of R-methadone plasma concentrations (1.06, 90% CI: 0.99-1.13) in the presence/absence of etravirine 100 mg twice daily after 14 days of concomitant therapy.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Clarke SM, Mulcahy FM, Tjia J, et al, “The Pharmacokinetics of Methadone in HIV-Positive Patients Receiving the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz,” <i>Br J Clin Pharmacol</i>, 2001, 51(3):213-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11298066\">[PubMed 11298066]</a></p>\n<p>2. Clarke SM, Mulcahy FM, Tjia J, et al, “Pharmacokinetic Interactions of Nevirapine and Methadone and Guidelines for Use of Nevirapine to Treat Injection Drug Users,” <i>Clin Infect Dis</i>, 2001, 33(9):1595-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11568856\">[PubMed 11568856]</a></p>\n<p>3. Stocker H, Kruse G, Kreckel P, et al, “Nevirapine Significantly Reduces the Levels of Racemic Methadone and (R)-Methadone in Human Immunodeficiency Virus-Infected Patients,” <i>Antimicrob Agents Chemother</i>, 2004, 48(11):4148-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15504834\">[PubMed 15504834]</a></p>\n<p>4. Esteban J, Pellin Mde L, Gimeno C, et al, “Increase of R-/S-Methadone Enantiomer Concentration Ratio in Serum of Patients Treated with Either Nevirapine or Efavirenz,” <i>Drug Metab Lett</i>, 2008, 2:269-79. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19356104\">[PubMed 19356104]</a></p>\n<p>5. Prescribing information. Edurant (rilpivirine). Raritan NJ: Tibotec Therapeutics, May 2011.</p>\n<p>6. Scholler-Gyure M, van den Brink W, Kakuda TN, et al, “Pharmacokinetic and Pharmacodynamic Study of the Concomitant Administration of Methadone and TMC125 in HIV-Negative Volunteers,” <i>J Clin Pharmacol</i>,2008,48(3):322-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18195053\">[PubMed 18195053]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3527":"<p><b>Title</b> Vitamin K Antagonists / Fenugreek</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fenugreek may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the prospective benefit of fenugreek supplementation in patients receiving vitamin K antagonists, and seek alternatives whenever possible. Monitor patients receiving these combinations closely for increases in INR and systemic effects of the vitamin K antagonist (particularly easy bruising and bleeding).</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The INR of a warfarin-stable patient increased from 2.3 to 3.4 within a few weeks of initiating the herbal supplements boldo and fenugreek in unspecified amounts.<sup>1</sup> The supplements were stopped and INR decreased to 2.6 within 1 week. Upon re-initiation of boldo and fenugreek, the patient's INR again increased to 3.4 within 2 weeks. An INR in the therapeutic range was re-established following a 15% warfarin dose reduction, with continuation of the supplements. <br><br>Whether the INR changes noted are attributable to fenugreek, boldo, or the combination is unknown. Fenugreek and boldo are both reported to contain coumarin constituents and as such may have potential to elevate INR in sufficient doses.<sup>2</sup> Some constituents of boldo may also inhibit platelet function via inhibition of thromboxane A2, which could contribute to bleeding risk but is unlikely to affect INR.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lambert JP and Cormier J, “Potential Interaction Between Warfarin and Boldo-Fenugreek,” <i>Pharmacotherapy</i>, 2001, 21(4):509-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11310527\">[PubMed 11310527]</a></p>\n<p>2. Izzo AA, Di Carlo G, Borrelli F, et al, “Cardiovascular Pharmacotherapy and Herbal Medicines: The Risk of Drug Interaction,” <i>Int J Cardiol</i>, 2005, 98(1):1-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15676159\">[PubMed 15676159]</a></p>\n<p>3. Teng CM, Hsueh CM, Chang YL, et al, “Antiplatelet Effects of Some Aporphine and Phenanthrene Alkaloids in Rabbits and Man,” <i>J Pharm Pharmacol</i>, 1997, 49(7):706-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9255715\">[PubMed 9255715]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3528":"<p><b>Title</b> Protease Inhibitors / Garlic</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Garlic may decrease the serum concentration of Protease Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of garlic supplements with protease inhibitors is not recommended. If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir*, Tipranavir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC, maximum plasma concentration (Cmax), and minimum plasma concentration (Cmin) of saquinavir (1200 mg 3 times/day x 3 days) were all approximately 50% lower with concurrent garlic caplets on days 18-20 of a 20-day course of garlic supplementation in a study of 10 healthy volunteers<sup>1</sup> An additional 3-day course of saquinavir following a 10-day washout period continued to demonstrate a significant, residual effect from the garlic (concentrations had increased to 60-70% of baseline values). Similarly, the saquinavir AUC was an average of 15% lower when a single dose of saquinavir was given after 21 days of garlic extract in a study of healthy volunteers.<sup>2</sup> An in vitro study also found that garlic extract significantly increased the cellular efflux of saquinavir and darunavir, even in the presence of low ritonavir concentrations.<sup>3</sup><br><br>The specific mechanism of this apparent is uncertain, but available data suggests that garlic induces p-glycoprotein-mediated efflux of saquinavir, resulting in decreased absorption/increased elimination.<sup>2,3</sup><br><br>As a result of data like these, saquinavir prescribing information recommends avoiding concurrent use of garlic supplements with saquinavir when possible.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Piscitelli SC, Burstein AH, Welden N, et al, “The Effect of Garlic Supplements on the Pharmacokinetics of Saquinavir,” <i>Clin Infect Dis</i>, 2002, 34(2):234-238. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11740713\">[PubMed 11740713]</a></p>\n<p>2. Hajda J, Rentsch KM, Gubler C, et al, “Garlic Extract Induces Intestinal P-glycoprotein, but Exhibits no Effect on Intestinal and Hepatic CYP3A4 in Humans,” <i>Eur J Pharm Sci</i>, 2010, Oct 7 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20933082\">[PubMed 20933082]</a></p>\n<p>3. Berginc K, Trdan T, Trontelj J, et al, “HIV Protease Inhibitors: Garlic Supplements and First-Pass Intestinal Metabolism Impact on the Therapeutic Efficacy,” <i>Biopharm Drug Dispos</i>, 2010, Oct 26 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20976826\">[PubMed 20976826]</a></p>\n<p>4. Prescribing information. Invirase (saquinavir). South San Francisco, CA: Genentech USA, Inc., 10/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3529":"<p><b>Title</b> Vitamin K Antagonists / Coenzyme Q-10</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Coenzyme Q-10 may diminish the anticoagulant effect of Vitamin K Antagonists. Coenzyme Q-10 may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for altered effects (reduced or increased) of vitamin K antagonists if used together with coenzyme Q-10.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Conflicting data exists. In a longitudinal study involving 171 patients receiving warfarin, coadministration of coenzyme Q-10 (n=15) was an independent risk factor for bleeding (OR=3.69).<sup>1</sup> In contrast, case reports describe a reduced anticoagulant effect of warfarin in patients following the addition of coenzyme Q-10 to the regimen.<sup>2</sup><br><br>The mechanism of any potential interaction is unclear. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. <i>Pharmacotherapy</i>. 2007;27(9):1237-1247. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17723077\">[PubMed 17723077]</a></p>\n<p>2. Spigset O. Reduced effect of warfarin caused by ubidecarenone. <i>Lancet</i>. 1994;344(8933):1372-1373. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7968059\">[PubMed 7968059]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3530":"<p><b>Title</b> Cefditoren / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine*, Lafutidine, Nizatidine, RaNITIdine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of cefditoren (400 mg single dose) was decreased 22% when coadministered with a single IV dose of famotidine (20 mg).<sup>1</sup> Impaired cefditoren absorption, caused by the increased gastric pH might explain this interaction, however the precise mechanism is unknown. Although the clinical significance of this interaction is unknown, cefditoren prescribing information recommends against concomitant use with H2-antagonists (eg, famotidine, ranitidine) as well as antacids.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Spectracef (cefditoren). Cary, NC: Cornerstone Therapeutics, 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3531":"<p><b>Title</b> Anakinra / Anti-TNF Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concomitant use may result in an increased risk of serious infection. The manufacturer of anakinra recommends avoiding use of anti-TNF agents together with anakinra.</p>\n<div>\n <p><b>Anti-TNF Agents Interacting Members</b> Adalimumab, Certolizumab Pegol, Etanercept*, Golimumab, InFLIXimab, Lenalidomide, Pomalidomide, Thalidomide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> According to anakinra prescribing information, in a 24-week study there were substantially more severe infections associated with combined anakinra and etanercept (an anti-TNF agent) (7%) than with etanercept alone (0%).<sup>1</sup> Additionally, 2% of patients receiving the combination of anakinra with an anti-TNF agent develop neutropenia (ANC less than 1x10<sup>9</sup>/L), further increasing the severe infection risk. Based on these factors, the manufacturer of anakinra does not recommend combined use of anakinra with anti-TNF agents.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Kineret (anakinra). Thousand Oaks, CA: Amgen, Inc, 12/2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3540":"<p><b>Title</b> Carvedilol / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Carvedilol. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects of carvedilol if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The steady state AUC of carvedilol was increased an average of 30% in a study of 10 healthy volunteers when coadministered with cimetidine (1000 mg/day).<sup>1</sup> No change in maximum serum concentration (Cmax) was observed. The mechanism of this interaction is uncertain but is likely related to the ability of cimetidine to inhibit enzyme(s) responsible for carvedilol metabolism (i.e., CYP2C9, CYP3A4, CYP2D6, others).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Coreg (carvedilol). Research Triangle Park, NC: GlaxoSmithKline, June 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3541":"<p><b>Title</b> Beta2-Agonists / Beta-Blockers (Nonselective)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of nonselective beta-blockers in patients treated with beta2-agonists. If used concomitantly, monitor closely for diminished bronchodilatory effects of the beta2-agonist.</p>\n<div>\n <p><b>Beta2-Agonists Interacting Members</b> Albuterol, Arformoterol, Bambuterol, Fenoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Pirbuterol, Ritodrine, Salmeterol, Terbutaline, Tulobuterol, Vilanterol</p>\n <p><b>Beta-Blockers (Nonselective) Interacting Members</b> Arotinolol, Carteolol (Ophthalmic), Carvedilol, Labetalol, Levobunolol, Metipranolol, Nadolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Nonselective beta-blockers (i.e., those that affect both beta1- and beta2-receptors) will antagonize the pharmacologic effects of beta2-agonists, and vice-versa. Of particular concern is the potential for the bronchodilatory effects of beta2-agonists to be abolished in a patient with asthma or chronic obstructive pulmonary disease (COPD). Nonselective beta-blockers, administered either systemically (e.g., oral, intravenous) or as an ophthalmic product, have been implicated in such interactions.<sup>1,2,3,4,5,6,7</sup> Prescribing information for most beta2-agonsts (albuterol, arformoterol, formoterol, levalbuterol, pirbuterol, salmeterol, terbutaline, indacaterol) advises against the use of nonselective beta-blockers in patients with asthma or COPD due to the potential for antagonism of the pulmonary effects of the beta-agonists and bronchospasm.<sup>8,9,10,11,12,13,14,15</sup> Only under certain circumstances (e.g., prophylaxis after myocardial infarction) should beta-blockers be used in these patients, and under these circumstances the use of cardioselective agents is preferred to nonselective agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Johnsson G, Svedmyr N, and Thiringer G, “Effects of Intravenous Propranolol and Metoprolol and Their Interactions With Isoprenaline on Pulmonary Function, Heart Rate and Blood Pressure in Asthmatics,” <i>Eur J Clin Pharmacol</i>, 1975, 8(3-4):175-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1233216\">[PubMed 1233216]</a></p>\n<p>2. Thiringer G and Svedmyr N, “Interaction of Orally-Administered Metoprolol, Practolol and Propranolol With Isoprenaline in Asthmatics,” <i>Eur J Clin Pharmacol</i>, 1976, 10:163.</p>\n<p>3. Charan NB and Lakshminarayan S, “Pulmonary Effects of Topical Timolol,” <i>Arch Intern Med</i>, 1980, 140(6):843. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7387281\">[PubMed 7387281]</a></p>\n<p>4. Jones FL and Ekberg NL, “Exacerbation of Obstructive Airway Disease by Timolol,” <i>JAMA</i>, 1980, 244(24):2730. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7441859\">[PubMed 7441859]</a></p>\n<p>5. Fogari R, Zoppi A, Tettamanti F, et al, “Comparison Effects of Celiprolol, Propranolol, Oxprenolol, and Atenolol on Respiratory Function in Hypertensive Patients With Chronic Obstructive Lung Disease,” <i>Cardiovasc Drugs Ther</i>, 1990, 4(4):1145-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1982059\">[PubMed 1982059]</a></p>\n<p>6. Van Der Woude HJ, Zaagsma J, Postma DS, et al, “Detrimental Effects of Beta-Blockers in COPD: A Concern for Nonselective Beta-Blockers,” <i>Chest</i>, 2005, 127(3):818-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15764762\">[PubMed 15764762]</a></p>\n<p>7. Brooks TW, Creekmore FM, Young DC, et al. “Rates of Hospitalizations and Emergency Department Visits in Patients With Asthma and Chronic Obstructive Pulmonary Disease Taking Beta-Blockers,” <i>Pharmacotherapy</i>, 2007, 27(5):684-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17461703\">[PubMed 17461703]</a></p>\n<p>8. Prescribing information. Albuterol sulfate HFA. Miami, FL: IVAX Pharmaceuticals, Inc., March 2007. </p>\n<p>9. Prescribing information. Brovana (arformoterol tartrate). Marlborough, MA: Sunovion Pharmaceuticals Inc., July 2011.</p>\n<p>10. Prescribing information. Foradil (formoterol fumarate). Whitehouse Station, NJ: Merck &amp; Co., Inc., May 2011.</p>\n<p>11. Prescribing information. Xopenex HFA (levalbuterol tartrate). Marlborough, MA: Sunovion Pharmaceuticals Inc., April 2011.</p>\n<p>12. Prescribing information. Maxair (pirbuterol acetate). Northridge, CA: 3M Pharmaceuticals, March 2006.</p>\n<p>13. Prescribing information. Serevent (salmeterol xinafoate). Research Triangle Park, NC: GlaxoSmithKline LLC, September 2011.</p>\n<p>14. Prescribing information. Terbutaline sulfate. Philadelphia, PA: Lannett Company, Inc., April 2011.</p>\n<p>15. Prescribing information. Arcapta (indacaterol). East Hanover, NJ: Novartis Pharmaceuticals Corporation, July 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3542":"<p><b>Title</b> Beta2-Agonists / Beta-Blockers (Beta1 Selective)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced effects of beta<sub>2</sub>-agonists if used concomitantly with a beta<sub>1</sub>-selective beta-blocker, especially if the beta-blocker is being used at higher dosages.</p>\n<div>\n <p><b>Beta2-Agonists Interacting Members</b> Albuterol, Arformoterol, Bambuterol, Fenoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Pirbuterol, Ritodrine, Salmeterol, Terbutaline, Tulobuterol, Vilanterol</p>\n <p><b>Beta-Blockers (Beta1 Selective) Interacting Members</b> Acebutolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Celiprolol, Esmolol, Metoprolol, Nebivolol</p>\n</div> \n<p><b>Discussion</b> All beta-blockers are capable of inducing brochoconstriction and/or causing bronchospasm.<sup>1,2</sup> The cardioselective (i.e., beta<sub>1</sub>-selective) beta-blockers are generally thought to have a lower potential for significant bronchoconstriction, particularly at lower doses. Beta<sub>1</sub>-selective agents are also thought to interfere less with the bronchodilatory effects of beta<sub>2</sub>-agonists. Several studies have shown that beta<sub>2</sub>-agonists maintain their ability to improve indices of ventilatory function in patients experiencing bronchoconstriction following administration of a beta<sub>1</sub>-selective beta-blocker (atenolol 100 mg orally, 3 mg IV; metoprolol 40-200 mg; acebutolol 300-400 mg; bisoprolol 10-20 mg).<sup>1,3,4,5,6,7</sup> One study also demonstrated that this preserved effectiveness of the beta<sub>2</sub>-agonists was in fact limited to the cardioselective beta-blockers as ventilatory function was not significantly improved by the beta<sub>2</sub>-agonist isoprenaline following administration of the non-selective beta-blockers propranolol, oxprenolol, timolol, or pindolol.<sup>1</sup><br><br>It is important to note that despite the lower risk of adverse pulmonary effects, the cardioselective beta-blockers can adversely affect pulmonary function in patients who are being treated with beta<sub>2</sub>-agonists. As an example of this, 4 of 30 asthmatic patients with coronary artery disease who were being treated with beta<sub>2</sub>-agonists experienced clinically significant bronchoconstriction in a study that was using beta-blockers (nearly all atenolol or metoprolol) to achieve a resting heart rate of less than 70 bpm.<sup>8</sup> One patient dropped out of the study due to bronchospasm, and three needed increased doses of their beta<sub>2</sub>-agonist to maintain baseline respiratory function. So, while most patients were able to tolerate therapy with a cardioselective beta-blocker without any adjustment to their other medications, more than 10% of the patients in this study did experience meaningful bronchoconstriction, even with “cardioselective” beta-blockers.<br><br>Regarding the effect of the beta<sub>2</sub>-agonist on the heart rate-lowering effectiveness of beta-blocker therapy, available data (though limited) suggest that this is mostly a theoretical concern and unlikely to be of much clinical significance. A study of 30 asthmatic patients with coronary artery disease showed that despite background beta<sub>2</sub>-agonist therapy, 29/30 patients were able to achieve a target heart rate of less than 70 bpm with few adverse effects.<sup>8</sup> Similarly, a study comparing several selective and non-selective beta-blockers reported that the beta<sub>2</sub>-agonist isoprenaline attentuated the heart rate-lowering effects of the beta-blockers very little, if at all, within 15 minutes of inhalation. <sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Decalmer PB, Chatterjee SS, Cruickshank JM, et al., “Beta-Blockers and Asthma,” <i>Br Heart J</i>, 1978, 40:184-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25075\">[PubMed 25075]</a></p>\n<p>2. Tafreshi MJ,Weinacker AB, “Beta-Adrenergic-Blocking Agents in Bronchospastic Diseases: A Therapeutic Dilemma,” <i>Pharmacotherapy</i>, 1999, 19:974-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10453968\">[PubMed 10453968]</a></p>\n<p>3. Boye NP,Vale JR, “Effect in Bronchial Asthma of a New Beta-Adrenergic Blocking Drug Atenolol (Ici 66, 082),” <i>Eur J Clin Pharmacol</i>, 1977, 11:11-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=319006\">[PubMed 319006]</a></p>\n<p>4. Mue S, Sasaki T, Shibahara S, et al., “Influence of Metoprolol on Hemodynamics and Respiratory Function in Asthmatic Patients,” <i>Int J Clin Pharmacol Biopharm</i>, 1979, 17:346-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=489201\">[PubMed 489201]</a></p>\n<p>5. Greefhorst AP,van Herwaarden CL, “Comparative Study of the Ventilatory Effects of Three Beta 1-Selective Blocking Agents in Asthmatic Patients,” <i>Eur J Clin Pharmacol</i>, 1981, 20:417-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6116610\">[PubMed 6116610]</a></p>\n<p>6. Lawrence DS, Sahay JN, Chatterjee SS, et al., “Asthma and Beta-Blockers,” <i>Eur J Clin Pharmacol</i>, 1982, 22:501-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6127219\">[PubMed 6127219]</a></p>\n<p>7. Lammers JW, Folgering HT,van Herwaarden CL, “Respiratory Tolerance of Bisoprolol and Metoprolol in Asthmatic Patients,” <i>J Cardiovasc Pharmacol</i>, 1986, 8 Suppl 11:S69-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2439802\">[PubMed 2439802]</a></p>\n<p>8. Khosla S, Kunjummen B, Khaleel R, et al., “Safety of Therapeutic Beta-Blockade in Patients with Coexisting Bronchospastic Airway Disease and Coronary Artery Disease,” <i>Am J Ther</i>, 2003, 10:48-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12522520\">[PubMed 12522520]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3543":"<p><b>Title</b> Tetracyclines / Quinapril</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Only oral preparations of tetracycline antibiotics are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Quinapril may decrease the serum concentration of Tetracyclines. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study cited in quinapril prescribing information, the absorption of tetracycline was decreased by 28-37% when coadministered with quinapril.<sup>1</sup> <br><br>This interaction is likely due to chelation of tetracycline by magnesium contained in the quinapril tablet formulation. Separating the doses of these products is expected to minimize this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Accupril (quinapril). New York, NY: Parke-Davis Division of Pfizer Inc, April 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3544":"<p><b>Title</b> Quinolones / Quinapril</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of quinolone antibiotics are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Quinapril may decrease the serum concentration of Quinolones. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin<br><b>Exception</b> LevoFLOXacin (Oral Inhalation)</p>\n</div> \n<p><b>Discussion</b> In a study cited in quinapril prescribing information, the absorption of tetracycline was decreased by 28-37% when coadministered with quinapril.<sup>1</sup> <br><br>This interaction is likely due to chelation of tetracycline by magnesium contained in the quinapril tablet formulation. Therefore, a similar concern exists for administration of quinapril with oral quinolone antibiotics. Separating the doses of these products is expected to minimize this interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Accupril (quinapril). New York, NY: Parke-Davis Division of Pfizer Inc, April 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3545":"<p><b>Title</b> Tricyclic Antidepressants / BuPROPion</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> BuPROPion may decrease the metabolism of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Seek alternatives to the concomitant use of bupropion and tricyclic antidepressants when possible. Monitor patients receiving these combinations closely for increased serum concentrations (when testing is available) and toxic effects of the tricyclic antidepressant.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, ClomiPRAMINE, Desipramine*, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline*, Trimipramine<br><b>Exceptions</b> Amoxapine, Protriptyline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC of desipramine (50 mg single dose) was increased approximately fivefold in 15 normal male subjects when administered following a course of bupropion (150 mg twice daily).<sup>1</sup> The effect is reported to have lasted for at least 7 days after the last dose of bupropion. Serum nortriptyline concentrations (75 mg/day) increased 185% in a patient following the addition of bupropion (150 mg twice daily).<sup>2</sup> The patient experienced confusion, falling, and lethargy. Dechallenge and rechallenge confirmed these effects. Bupropion is a CYP2D6 inhibitor and the tricyclics (most) are CYP2D6 substrates. Their concomitant use appears to reduce the clearance of the tricyclic. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wellbutrin [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc, 2000.</p>\n<p>2. Weintraub D, “Nortriptyline Toxicity Secondary to Interaction With Bupropion Sustained-Release,” <i>Depress Anxiety</i>, 2001, 13(1):50-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11233461\">[PubMed 11233461]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3546":"<p><b>Title</b> CarBAMazepine / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of CarBAMazepine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of carbamazepine if grapefruit/grapefruit juice consumption is initiated or increased. If patients regularly using this combination stop or decrease regular grapefruit/grapefruit juice consumption, monitor closely for evidence of decreased carbamazepine effects/concentrations.</p> \n<p><b>Discussion</b> The steady state maximum and minimum serum concentrations and AUC of carbamazepine (200 mg 3 times/day) were all increased approximately 40% when the carbamazepine was administered with grapefruit juice in a study of 10 patients.<sup>1</sup> A case report also describes increased serum carbamazepine concentrations, and associated toxicity, in a patient following the addition of a single yellow grapefruit to his daily diet.<sup>2</sup> A 20% reduction in carbamazepine dosage was needed to maintain acceptable serum carbamazepine concentrations.<br><br>Some constituents in grapefruit juice are known to inhibit CYP3A4,<sup>3</sup> which is the enzyme primarily responsible for carbamazepine metabolism. It is likely that concomitant administration of grapefruit with carbamazepine will cause a reduction in the CYP3A4-mediated metabolism of carbamazepine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Garg SK, Kumar N, Bhargava VK, Prabhakar SK. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. <i>Clin Pharmacol Ther</i>. 1998;64(3):286-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757152\">[PubMed 9757152]</a></p>\n<p>2. Bonin B, Vandel P, Vandel S, Kantelip JP. Effect of grapefruit intake on carbamazepine bioavailability: a case report. <i>Therapie</i>. 2001;56(1):69-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11322025\">[PubMed 11322025]</a></p>\n<p>3. Ho PC, Saville DJ, Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. <i>J Pharm Pharm Sci</i>. 2001;4(3):217-227. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11737987\">[PubMed 11737987]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3547":"<p><b>Title</b> Cisapride / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Cisapride. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Minimize consumption of grapefruit/grapefruit juice during cisapride therapy. Monitor for toxic effects of cisapride (eg, QT interval prolongation, ventricular arrhythmia) if grapefruit/grapefruit juice is added/increased in the diet.</p> \n<p><b>Discussion</b> In a clinical study of 12 healthy volunteers, the AUC (a measure of drug exposure) of cisapride (10 mg single dose) was increased 51% when administered with a glass of grapefruit juice (250 mL).<sup>1</sup> In a second study of healthy subjects using the same dosage regimen, grapefruit juice increased cisapride AUC and maximum concentration (Cmax) by approximately 39% and 34%, respectively.<sup>2</sup> In a third study of healthy volunteers, repeated dosing of double strength concentrated grapefruit juice (200 mL three times daily for 2 days, then with cisapride, 30 min, and 90 min post dose) with cisapride (10 mg single dose) increased cisapride AUC and Cmax by 144% and 81%, respectively.<sup>3</sup><br><br>The mechanism of this interaction is likely related to the ability of grapefruit juice to reduce cisapride metabolism by inhibiting CYP3A4 isoenzymes. This effect appears to be greatest on first pass metabolism, as studies with single doses of grapefruit juice did not show an increase in elimination half life of cisapride.<sup>1,2</sup> However, repeated dosing of grapefruit juice did have a significant effect of increasing elimination half life.<sup>3</sup> Cisapride metabolism is stereoselective, favoring metabolism of the (+) enantiomer, but the magnitude of drug interaction with grapefruit juice is similar with both the (+) and (-) enantiomers in healthy subjects.<sup>4</sup> Grapefruit juice coadministration with cisapride had no impact on QT interval in healthy volunteers in the above studies, but this interaction could theoretically increase the risk of cardiac toxicity (eg, ventricular arrhythmia, torsades de pointes) in susceptible patients.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Offman EM, Freeman DJ, Dresser GK, et al, “Red Wine-Cisapride Interaction: Comparison With Grapefruit Juice,” <i>Clin Pharmacol Ther</i>, 2001, 70(1):17-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11452240\">[PubMed 11452240]</a></p>\n<p>2. Gross AS, Goh YD, Addison RS, et al, “Influence of Grapefruit Juice on Cisapride Pharmacokinetics,” <i>Clin Pharmacol Ther</i>, 1999, 65(4):395-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10223776\">[PubMed 10223776]</a></p>\n<p>3. Kivisto KT, Lilja JJ, Backman JT, et al, “Repeated Consumption of Grapefruit Juice Considerably Increases Plasma Concentrations of Cisapride,” <i>Clin Pharmacol Ther</i>, 1999, 66(5):448-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10579471\">[PubMed 10579471]</a></p>\n<p>4. Desta Z, Kivisto KT, Lilja JJ, et al, “Stereoselective Pharmacokinetics of Cisapride in Healthy Volunteers and the Effect of Repeated Administration of Grapefruit Juice,” <i>Br J Clin Pharmacol</i>, 2001, 52(4):399-407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11678783\">[PubMed 11678783]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3548":"<p><b>Title</b> Vitamin K Antagonists / Capecitabine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Capecitabine may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor INR and signs/symptoms of bleeding closely when starting or stopping capecitabine in a patient receiving a vitamin K antagonist (e.g., warfarin). Anticoagulant dose adjustment will likely be necessary, and effects may increase with subsequent cycles of capecitabine.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Capecitabine prescribing information contains a black box warning regarding an interaction with coumarin anticoagulants.<sup>1</sup> Case reports and retrospective studies have reported numerous instances of bleeding, elevated INR, and/or decreased warfarin dose requirement in patients receiving warfarin that occurred within days to months after initiating capecitabine.<sup>1,2,3,4,5,6,7</sup> Many of the reported interactions have resulted in severe bleeding, large INR changes, and/or substantial reductions in warfarin dose requirements.<br><br>The mechanism of this interaction appears to fluorouracil-mediated inhibition of S-warfarin (most potent enantiomer) metabolism, a process normally dependent on CYP2C9. Capecitabine is a prodrug of floxuridine, which is partially converted further to fluorouracil in vivo.<sup>1</sup> S-warfarin AUC and half-life were increased by 57% and 51%, respectively, with concurrent capecitabine, with no associated changes in R-warfarin pharmacokinetics, in a small pharmacokinetic study (n=4).<sup>8</sup> Though neither floxuridine or fluorouracil appear to have any direct inhibitory effect on CYP2C9 in microsomal studies,<sup>9,10</sup> studies in rats and patients with colorectal cancer have demonstrated decreased CYP2C9 activity (i.e., phenytoin hydroxylation<sup>9</sup> and losartan/E3174 ratio<sup>11</sup>) following treatment with both floxuridine<sup>9</sup> and fluorouracil<sup>9,11</sup> treatment. Of note, the inhibition appears time- and/or dose-dependent with greater inhibition after 3 cycles of fluorouracil (5.3-fold decrease) than after 1 cycle (28% decrease).<sup>11</sup> An observation that the warfarin dose reductions required during fluorouracil therapy increase with each cycle of fluorouracil further support this time-/dose-dependence.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Xeloda (capecitabine) [prescribing information]. Nutley, NJ: Roche Pharmaceuticals; April 2006.</p>\n<p>2. Copur MS, Ledakis P, Bolton M, et al. An adverse interaction between warfarin and capecitabine: a case report and review of the literature. <i>Clin Colorectal Cancer</i>. 2001;1(3):182-184. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12450435\">[PubMed 12450435]</a></p>\n<p>3. Isaacs K, Haim N. Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding: case report and review of the literature. <i>J Chemother</i>. 2005;17(3):339-342. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16038530\">[PubMed 16038530]</a></p>\n<p>4. Janney LM, Waterbury NV. Capecitabine-warfarin interaction. <i>Ann Pharmacother</i>. 2005;39(9):1546-1551. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16014372\">[PubMed 16014372]</a></p>\n<p>5. Shah HR, Ledbetter L, Diasio R, Saif MW. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. <i>Clin Colorectal Cancer</i>. 2006;5(5):354-358. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16512995\">[PubMed 16512995]</a></p>\n<p>6. Yildirim Y, Ozyilkan O, Akcali Z, Basturk B. Drug interaction between capecitabine and warfarin: a case report and review of the literature. <i>Int J Clin Pharmacol Ther</i>. 2006;44(2):80-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16502767\">[PubMed 16502767]</a></p>\n<p>7. Ikenishi M, Ueda M, Kuroda A, et al. A study on drug interaction between warfarin and capecitabine with special reference to the co-administered term or the discontinuation term of capecitabine. <i>Gan To Kagaku Ryoho</i>. 2015;42(7):833-839. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26197745\">[PubMed 26197745]</a></p>\n<p>8. Camidge R, Reigner B, Cassidy J, et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. <i>J Clin Oncol</i>. 2005;23(21):4719-4725. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16034047\">[PubMed 16034047]</a></p>\n<p>9. Konishi H, Yoshimoto T, Morita K, Minouchi T, Sato T, Yamaji A. Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats. <i>J Pharm Pharmacol</i>. 2003;55(1):143-149. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12625878\">[PubMed 12625878]</a></p>\n<p>10. Park JY, Kim KA. Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes. <i>Eur J Clin Pharmacol</i>. 2003;59(5-6):407-409. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12904931\">[PubMed 12904931]</a></p>\n<p>11. Gunes A, Coskun U, Boruban C, et al. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. <i>Basic Clin Pharmacol Toxicol</i>. 2006;98(2):197-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16445595\">[PubMed 16445595]</a></p>\n<p>12. Davis DA, Fugate SE. Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-Fluorouracil therapy. <i>Pharmacotherapy</i>. 2005;25(3):442-447. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15843293\">[PubMed 15843293]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3551":"<p><b>Title</b> Thiopurine Analogs / 5-Aminosalicylic Acid Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> 5-Aminosalicylic Acid Derivatives may decrease the metabolism of Thiopurine Analogs. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for toxic effects of thiopurine analogs when used in combination with aminosalicylic acid derivatives. This is of particular importance in patients who are unusually sensitive to the myelosuppressive effects of these agents due to a deficiency of thiopurine methyltransferase (TPMT), an enzyme responsible for thiopurine metabolism.</p>\n<div>\n <p><b>5-Aminosalicylic Acid Derivatives Interacting Members</b> Balsalazide, Mesalamine, Olsalazine*, SulfaSALAzine*</p>\n <p><b>Thiopurine Analogs Interacting Members</b> AzaTHIOprine, Mercaptopurine*, Thioguanine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A 1995 report demonstrated the ability of sulfasalazine to inhibit thiopurine methyltransferase (TPMT).<sup>1</sup> A subsequent case report described 2 episodes of bone marrow suppression during concomitant 6-mercaptopurine and olsalazine therapy.<sup>2</sup> The patient was discovered to possess a relatively low baseline level of TPMT activity. It is purported that the olsalazine further inhibited this enzyme activity, resulting in decreased mercaptopurine clearance and subsequent toxicity. Other thiopurine analogs are expected to be similarly affected. This interaction is likely of limited consequence in patients with normal levels of TPMT activity. However, those with an inherited deficiency, increased thiopurine toxicity might be expected. The manufacturers of mercaptopurine and thioguanine include this potential concern in their official product labeling.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Szumlanski CL and Weinshilboum RM, “Sulphasalazine Inhibition of Thiopurine Methyltransferase: Possible Mechanism for Interaction With 6-mercaptopurine and Azathioprine,” <i>Br J Clin Pharmacol</i>, 1995, 39(4):456-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7640156\">[PubMed 7640156]</a></p>\n<p>2. Lewis LD, Benin A, Szumlanski CL, et al, “Olsalazine and 6-mercaptopurine-Related Bone Marrow Suppression: A Possible Drug-Drug Interaction,” <i>Clin Pharmacol Ther</i>, 1997, 62(4):464-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9357398\">[PubMed 9357398]</a></p>\n<p>3. Purinethol [package insert]. Sellersville, PA: Gate Pharmaceuticals, 2003.</p>\n<p>4. Tabloid [package insert]. Research Triangle Park, NC: GlaxoSmithKline, 2001.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3553":"<p><b>Title</b> Acetaminophen / Gastrointestinal Agents (Prokinetic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Gastrointestinal Agents (Prokinetic) may increase the serum concentration of Acetaminophen. Maximum concentration may be reached more quickly but there is probably no impact on total acetaminophen exposure. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Gastrointestinal Agents (Prokinetic) Interacting Members</b> Bromopride, Cisapride*, Metoclopramide*, Mosapride</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Available evidence suggests that both metoclopramide (oral and IV) and cisapride may modestly increase the rate, but not necessarily the extent, of absorption of acetaminophen.<sup>1,2,3,4,5,6</sup> This may shorten the time to reach maximum concentration but probably has no impact on total acetaminophen exposure. Two small studies showed little or no trend toward this effect, one using rectal metoclopramide 30 minutes prior to acetaminophen<sup>7</sup> and the other using cisapride 10 mg or 20 mg concurrently with acetaminophen.<sup>8</sup><br><br>This interaction is probably due to advancement of the acetaminophen to its site of absorption quicker in the presence of the prokinetic agents. The onset of analgesia may be sped, but the clinical significance of this effect is questionable. Additional information suggests that cisapride may also inhibit acetaminophen glucuronidation<sup>3</sup> which could theoretically increase total acetaminophen exposure, but studies have generally shown no impact of cisapride on total acetaminophen exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nimmo J, Heading, RC, Tothill, et al, “Pharmacological Modification of Gastric Emptying: Effects of Propantheline and Metoclopramide on Paracetamol Absorption,” <i>Br Med J</i>, 1973, 1:587. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4694406\">[PubMed 4694406]</a></p>\n<p>2. Crome P, Kimber GR, Wainscott G, et al, “The Effect of the Simultaneous Administration of Oral Metoclopramide on the Absorption of Paracetamol in Healthy Volunteers,” <i>Br J Clin Pharmacol</i>, 1981, 11:430-1P.</p>\n<p>3. Itoh H, Nagano T, and Takeyama M, “Cisapride Raises the Bioavailability of Paracetamol by Inhibiting Its Glucuronidation in Man,” <i>J Pharm Pharmacol</i>, 2001, 53(7):1041-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11480539\">[PubMed 11480539]</a></p>\n<p>4. van Wyk M, Sommers DK, Meyer EC, et al, “The Mean Cumulative Fraction Absorbed-Time Profiles of Paracetamol as an Index of Gastric Emptying,” <i>Methods Find Exp Clin Pharmacol</i>, 1990, 12(4):291-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2374477\">[PubMed 2374477]</a></p>\n<p>5. van Wyk M, Sommers DK and Moncrieff J, “Influence of Cisapride, Metoclopramide and Loperamide on Gastric Emptying of Normal Volunteers as Measured by Means of the Area Under the Curve of the Cumulative Fraction Absorbed-Time Profiles of Paracetamol,” <i>Methods Find Exp Clin Pharmacol</i>, 1992, 14(5):379-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1513194\">[PubMed 1513194]</a></p>\n<p>6. Dougall JR, Cunningham B and Nimmo WS, “Paracetamol Absorption from Paramax, Panadol and Solpadeine,” <i>Br J Clin Pharmacol</i>, 1983, 15(4):487-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6849786\">[PubMed 6849786]</a></p>\n<p>7. Tokola RA, “The Effect of Metoclopramide and Prochlorperazine on the Absorption of Effervescent Paracetamol in Migraine,” <i>Cephalalgia</i>, 1988, 8(3):139-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=31970094\">[PubMed 31970094]</a></p>\n<p>8. Rowbotham DJ, Parmacott S and Nimmo WS, “No Effect of Cisapride on Paracetamol Absorption after Oral Simultaneous Administration,” <i>Eur J Clin Pharmacol</i>, 1992, 42(2):235-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1618258\">[PubMed 1618258]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3554":"<p><b>Title</b> TraZODone / Venlafaxine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Venlafaxine may enhance the serotonergic effect of TraZODone. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of serotonin syndrome during concomitant use of venlafaxine and trazodone, both of which possess serotonergic properties.</p> \n<p><b>Discussion</b> One published case report describes a 50 year-old patient with a medical history significant for depression, HIV infection, and hepatitis C who experienced signs and symptoms of serotonin syndrome approximately 2-3 weeks after starting concurrent of venlafaxine (titrated up to 225 mg/day) and trazodone (100 mg at bedtime).<sup>1</sup> The patient's other medications included docusate sodium and methadone (120 mg/day). Trazodone and venlafaxine both possess serotonergic effects, causing the authors of this report to attribute the patient's serotonin syndrome largely to an interaction between these two drus. Of note, methadone may also have serotonin-altering effects, meaning that it may have also played a role in this case, even though the authors of the case report mostly dismissed this possibility based on the patient's history of safely using methadone together with selective serotonin reuptake inhibitors (SSRIs).</p> \n<p><b>Footnotes</b> </p>\n<p>1. McCue RE and Joseph M, “Venlafaxine- and Trazodone-Induced Serotonin Syndrome,” <i>Am J Psychiatry</i>, 2001, 158(12):2088-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11729039\">[PubMed 11729039]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3555":"<p><b>Title</b> Quinolones / Calcium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): Only oral preparations of quinolone antibiotics and calcium salts are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Salts may decrease the absorption of Quinolones. Of concern only with oral administration of both agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate*, Calcium Carbonate, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil<br><b>Exception</b> Calcium Chloride</p>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin, Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin<br><b>Exceptions</b> LevoFLOXacin (Oral Inhalation), Moxifloxacin (Systemic)</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The ability of multivalent cations to reduce the absorption of oral quinolones is well-established. It is believed that the 3-carbonyl and 4-oxo functional groups on the antibiotic forms a chelate with the cations resulting in inactive antimicrobials.<sup>1,2,3</sup> This interaction appears most significant with aluminum and magnesium ions, to a lesser extent with calcium ions, and probably nonexistent with sodium ions. The reduction in quinolone absorption can significantly affect C<sub>max</sub> and percent bioavailability, at times inhibiting the therapeutic effectiveness of the antibiotic. Calcium-containing antacids have been reported to reduce quinolone bioavailability to the following percentages: Ciprofloxacin (59%); levofloxacin (97%); lomefloxacin (98%); and norfloxacin (37%).<sup>4,5,6,7,8,9,10</sup> Calcium acetate has been reported to decrease the AUC of oral ciprofloxacin by 51%.<sup>11</sup> Calcium administration appears to affect the rate, but not the extent, of moxifloxacin absorption.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hoffken G, Borner K, Glatzel PD, et al, “Reduced Enteral Absorption of Ciprofloxacin in the Presence of Antacids,” <i>Eur J Clin Microbiol</i>, 1985, 4:345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3160584\">[PubMed 3160584]</a></p>\n<p>2. Schentag JJ, Watson WA, Nix DE, et al, “Time-Dependent Interactions Between Antacids and Quinolone Antibiotics,” <i>Clin Pharmacol Ther</i>, 1988, 43:135.</p>\n<p>3. Shimada J, Shiba K, Oguma T, et al, “Effect of Antacid on Absorption of the Quinolone Lomefloxacin,” <i>Antimicrob Agents Chemother</i>, 1992, 36:1219-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1329615\">[PubMed 1329615]</a></p>\n<p>4. Shiba K, Sakai O, Shimada J, et al, “Effects of Antacids, Ferrous Sulphate and Ranitidine on Absorption of DR-3355 in Humans,” <i>Antimicrob Agents Chemother</i>, 1992, 36:2270-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1444308\">[PubMed 1444308]</a></p>\n<p>5. Sahai J, Healey DP, Stotka J, et al, “The Influence of Chronic Administration of Calcium Carbonate on the Bioavailability of Oral Ciprofloxacin,” <i>Br J Clin Pharmacol</i>, 1993, 35:302-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8471407\">[PubMed 8471407]</a></p>\n<p>6. Frost RW, Lettieri JT, Noe A, et al, “Effect of Aluminum Hydroxide and Calcium Carbonate Antacids on Ciprofloxacin Bioavailability,” <i>Clin Pharmacol Ther</i>, 1989, 45:165.</p>\n<p>7. Lehto PL and Kivisto KT, “Different Effects of Products Containing Metal Ions on the Absorption of Lomefloxacin,” <i>Clin Pharmacol Ther</i>, 1994, 56:477-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7955811\">[PubMed 7955811]</a></p>\n<p>8. Nix DE, Wilton JH, Ronald B, et al, “Inhibition of Norfloxacin Absorption by Antacids,” <i>Antimicrob Agents Chemother</i>, 1990, 34:432-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2334155\">[PubMed 2334155]</a></p>\n<p>9. Nix DE, Wilton JH, Schentag JJ, et al, “Inhibition of Norfloxacin Absorption by Antacids and Sucralfate,” <i>Rev Infect Dis</i>, 1989, II(Suppl 5):S1096.</p>\n<p>10. Okhamafe AO, Akerele JO, and Chukuka CS, “Pharmacokinetic Interactions of Norfloxacin With Some Metallic Medicinal Agents,” <i>Int J Pharm</i>, 1991, 68:11-18.</p>\n<p>11. Kays MB, Overholser BR, Mueller BA, et al, “Effects of Sevelamer Hydrochloride and Calcium Acetate on the Oral Bioavailability of Ciprofloxacin,” <i>Am J Kidney Dis</i>, 2003, 42(6):1253-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14655198\">[PubMed 14655198]</a></p>\n<p>12. Staff H, Wandel C, Delesen H, et al, “Effect of Calcium Supplements on the Oral Bioavailability of Moxifloxacin in Healthy Male Volunteers,” <i>Clin Pharmacokinet</i>, 2001, 40(Suppl 1):27-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11352439\">[PubMed 11352439]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3556":"<p><b>Title</b> Quinolones / Magnesium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b> (oral): This interaction is only expected with the use of oral magnesium salts and oral quinolone antibiotics. Intravenous preparations are not expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Magnesium Salts may decrease the serum concentration of Quinolones. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Administer oral quinolones at least several hours before (4 h for moxifloxacin, pefloxacin, and sparfloxacin, 2 h for others) or after (8 h for moxifloxacin, 6 h for ciprofloxacin and delafloxacin, 4 h for lomefloxacin and pefloxacin, 3 h for gemifloxacin, 2 h for levofloxacin, norfloxacin, ofloxacin or nalidixic acid) oral magnesium salts. Monitor for diminished effects of the quinolone if this duration of dose separation cannot be achieved.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin<br><b>Exception</b> LevoFLOXacin (Oral Inhalation)</p>\n</div> \n<p><b>Discussion</b> The ability of magnesium salts and/or magnesium containing antacids to reduce the absorption of oral quinolones is well-established and has been demonstrated in numerous pharmacokinetic studies.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13</sup> Various oral magnesium salts have been reported to reduce quinolone AUCs by the following percentages: ciprofloxacin (33% to 85%), enoxacin (73%), gemifloxacin (85%), levofloxacin (22%), lomefloxacin (41%), moxifloxacin (59%), norfloxacin (99%), ofloxacin (21%), sparfloxacin (23%), trovafloxacin (66%), and pefloxacin (54%).<sup>1,2,3,4,5,6,7,8,9,10,13</sup> The maximum serum concentrations of oral quinolones were reduced by the following percentages: ciprofloxacin (85% to 94%), enoxacin (70%), gemifloxacin (87%), levofloxacin (38%), lomefloxacin (46%), moxifloxacin (61%), norfloxacin (95%), ofloxacin (30%), sparfloxacin (29%), trovafloxacin (60%), and pefloxacin (61%).<sup>1,2,3,4,5,6,7,8,9,10,11,13</sup> Observational studies have reported significantly lower ciprofloxacin peak and trough levels in patients taking antacids compared with those not taking antacids.<sup>14,15</sup> Case reports also describe quinolone treatment failure when combined with magnesium salts.<sup>16,17</sup><br><br>In contrast, 2 studies report little to no change in ofloxacin pharmacokinetics when combined with magnesium trisilicate<sup>18</sup> or a magnesium containing antacid (magnesium hydroxide/aluminum hydroxide).<sup>19</sup><br><br>The effect of dose separation has been evaluated in numerous studies.<sup>1,2,3,6,7,8,9,10</sup> Depending on the drug and the interval chosen for evaluation, dose separation reduces the magnitude of or eliminates the interaction. Specific dose separation recommendations aimed at minimizing these interactions are offered by the manufacturers of oral quinolone products.<sup>20,21,22,23,24,25,26,27,28,29,30</sup><br><br>The suspected primary mechanisms of these interactions are formation of an insoluble complex between the quinolone antibiotic and the magnesium salt that is not readily absorbed from the GI tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stass H, Bottcher MF, Ochmann K. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers. <i>Clin Pharmacokinet</i>. 2001;40(suppl 1):39-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11352441\">[PubMed 11352441]</a></p>\n<p>2. Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers. <i>Chemotherapy</i>. 1999;45(6):504-511. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10567782\">[PubMed 10567782]</a></p>\n<p>3. Johnson RD, Dorr MB, Talbot GH, Caille G. Effect of Maalox on the oral absorption of sparfloxacin. <i>Clin Ther</i>. 1998;20(6):1149-1158. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9916608\">[PubMed 9916608]</a></p>\n<p>4. Shiba K, Sakai O, Shimada J, Okazaki O, Aoki H, Hakusui H. Effects of antacids, ferrous sulfate, and ranitidine on the absorption of DR-3355 in humans. <i>Antimicrobial Agents Chemother</i>. 1992;36(10):2270-2274. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1444308\">[PubMed 1444308]</a></p>\n<p>5. Shimada J, Shiba K, Oguma T, et al. Effect of antacid on absorption of the quinolone lomefloxacin. <i>Antimicrob Agents Chemother</i>. 1992;36(6):1219-1224. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1329615\">[PubMed 1329615]</a></p>\n<p>6. Flor S, Guay DR, Opsahl JA, Tack K, Matzke GR. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. <i>Antimicrob Agents Chemother</i>. 1990;34(12):2436-2438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2088202\">[PubMed 2088202]</a></p>\n<p>7. Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A. Inhibition of norfloxacin absorption by antacids. <i>Antimicrob Agents Chemother</i>. 1990;34(3):432-435. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2334155\">[PubMed 2334155]</a></p>\n<p>8. Nix DE, Watson WA, Lener ME, et al. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. <i>Clin Pharmacol Ther</i>. 1989;46(6):700-705. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2598571\">[PubMed 2598571]</a></p>\n<p>9. Grasela TH Jr, Schentag JJ, Sedman AJ, et al. Inhibition of enoxacin absorption by antacids or ranitidine. <i>Antimicrob Agents Chemother</i>. 1989;33(5):615-617. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2751276\">[PubMed 2751276]</a></p>\n<p>10. Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. <i>J Antimicrob Chemother</i>. 1997;39(suppl B):93-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9222077\">[PubMed 9222077]</a></p>\n<p>11. Hoffken G, Borner K, Glatzel PD, Koeppe P, Lode H. Reduced enteral absorption of ciprofloxacin in the presence of antacids. <i>Eur J Clin Microbiol</i>. 1985;4(3):345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3160584\">[PubMed 3160584]</a></p>\n<p>12. Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW. Norfloxacin interaction with antacids and minerals. <i>Br J Clin Pharmacol</i>. 1992;33(1):115-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1540482\">[PubMed 1540482]</a></p>\n<p>13. Jaehde U, Sorgel F, Stephan U, Schunak W. Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. <i>Antimicrob Agents Chemother</i>. 1994;38(5):1129-1133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8067750\">[PubMed 8067750]</a></p>\n<p>14. Fleming LW, Moreland TA, Stewart WK, Scott AC. Ciprofloxacin and antacids. <i>Lancet</i>. 1986;2(8501):294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2874321\">[PubMed 2874321]</a></p>\n<p>15. Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. Ciprofloxacin and antacids. <i>Lancet</i>. 1986;2(8497):48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2873348\">[PubMed 2873348]</a></p>\n<p>16. Noyes M, Polk RE. Norfloxacin and absorption of magnesium-aluminum. <i>Ann Intern Med</i>. 1988;109(2):168-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3382110\">[PubMed 3382110]</a></p>\n<p>17. Suda KJ, Garey KW, Danziger LH. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. <i>Pharm World Sci</i>. 2005;27(2):81-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15999916\">[PubMed 15999916]</a></p>\n<p>18. Akerele JO, Okhamafe AO. Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics. <i>J Antimicrob Chemother</i>. 1991;28(1):87-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1663108\">[PubMed 1663108]</a></p>\n<p>19. Maesen FP, Davies BI, Geraedts WH, Sumajow CA. Ofloxacin and antacids. <i>J Antimicrob Chemother</i>. 1987;19(6):848-850. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3475268\">[PubMed 3475268]</a></p>\n<p>20. Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2015.</p>\n<p>21. Factive (gemifloxacin) [prescribing information]. Toronto, Ontario, Canada: Merus Labs; August 2013. </p>\n<p>22. Levaquin (levofloxacin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; May 2014.</p>\n<p>23. Maxaquin (lomefloxacin) [prescribing information]. New York, NY: Pfizer Inc; March 2005.</p>\n<p>24. Avelox (moxifloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; November 2014.</p>\n<p>25. Neggram (nalidixic acid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2012.</p>\n<p>26. Noroxin (norfloxacin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2013.</p>\n<p>27. Floxin (ofloxacin) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; February 2011.</p>\n<p>28. Zagam (sparfloxacin) [prescribing information]. Research Triangle Park, NC: Bertek Pharmaceuticals Inc; April 2003.</p>\n<p>29. Baxdela (delafloxacin) [prescribing information]. Lincolnshire, IL: Melinta Therapeutics Inc; June 2017.</p>\n<p>30. Pefloxacin tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199101448 Accessed October 26, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3558":"<p><b>Title</b> Bisphosphonate Derivatives / Aminoglycosides</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase monitoring of serum calcium, serum magnesium, and serum creatinine/renal function during concomitant use of bisphosphonate derivatives and aminoglycoside antibiotics. The interaction-related effects of the aminoglycosides can last for several days/weeks following discontinuation.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin*, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n <p><b>Bisphosphonate Derivatives Interacting Members</b> Alendronate, Clodronate*, Etidronate, Ibandronate, Pamidronate, Risedronate, Tiludronate, Zoledronic Acid</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Two case reports highlight the possibility that concomitant use of aminoglycoside antibiotics and bisphosphonate derivatives can result in severe, even life-threatening, hypocalcemia.<sup>1,2</sup> A postulated mechanism for this interaction is based on the association of aminoglycosides with hypocalcemia,<sup>3,4,5</sup> an effect attributed to inhibition of the activity of the parathyroid glands (via drug-induced kidney damage and subsequent loss of magnesium) and reduced parathyroid hormone (PTH) production. PTH production is a normal homeostatic response to hypocalcemia resulting in increased serum calcium, and is the process that normally prevents the development of hypocalcemia during bisphosphonate administration.<br><br>Some, but not all, bisphosphonate manufacturers warn of this potential interaction.<sup>6,7,8</sup> Some also caution that, since the bisphosphonates are renally eliminated, concurrent use with nephrotoxic drugs (e.g., aminoglycosides) should be performed with care and close monitoring.<sup>6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mayordomo JI, Rivera F. Severe hypocalcaemia after treatment with oral clodronate and aminoglycoside. <i>Ann Oncol</i>. 1993;4(5):432-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8353080\">[PubMed 8353080]</a></p>\n<p>2. Pedersen-Bjergaard U, Myhre J. Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside. <i>BMJ</i>. 1991;302(6771):295. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1825614\">[PubMed 1825614]</a></p>\n<p>3. Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. <i>J Bone Miner Res</i>. 2013;28(10):2049-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23907861\">[PubMed 23907861]</a></p>\n<p>4. Shih AW, Weir MA, Clemens KK, et al. Oral bisphosphonate use in the elderly is not associated with acute kidney injury. <i>Kidney Int</i>. 2012;82(8):903-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22695327\">[PubMed 22695327]</a></p>\n<p>5. Zuradelli M, Masci G, Biancofiore G, et al. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid. <i>Oncologist</i>. 2009;14(5):548-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19411682\">[PubMed 19411682]</a></p>\n<p>6. Prescribing information. Zometa (zoledronic acid). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 09/2013.</p>\n<p>7. Product monograph. Zometa (zoledronic acid). Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc., July 2013.</p>\n<p>8. Prescribing information. Aredia (pamidronate). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 05/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3559":"<p><b>Title</b> Bisphosphonate Derivatives / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Loop Diuretics may enhance the hypocalcemic effect of Bisphosphonate Derivatives. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Bisphosphonate Derivatives Interacting Members</b> Alendronate, Clodronate, Etidronate, Ibandronate, Pamidronate, Risedronate, Tiludronate, Zoledronic Acid</p>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> Zoledronic acid prescribing information advises caution when the drug is used in combination with loop diuretics due to an increased risk of hypocalcemia.<sup>1,2</sup> This combination may be intentionally employed for certain conditions, such as treatment of hypercalcemia due to malignancy. Both the bisphosphonates and loop diuretics independently lower serum calcium concentrations (via distinct mechanisms), accounting for the increased risk of hypocalcemia with their combined use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zometa (zoledronic acid). East Hanover, NJ: Novartis Pharmaceuticals Corporation, January 2010.</p>\n<p>2. Prescribing information. Reclast (zoledronic acid). East Hanover, NJ: Novartis Pharmaceuticals Corporation, October 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3562":"<p><b>Title</b> Repaglinide / HMG-CoA Reductase Inhibitors (Statins)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Repaglinide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased repaglinide effects (ie, hypoglycemia) if combined with HMG-CoA reductase inhibitors (statins).</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 12 healthy male subjects, the mean AUC and maximum serum concentration (Cmax) of repaglinide (2 mg 3 times daily x 5 days) increased 8% and 26%, respectively, when coadministered with simvastatin (20 mg daily x 5 days).<sup>1</sup> A higher number of adverse events were reported in subjects who received both repaglinide and simvastatin (45 events) compared with administration of repaglinide alone (23 events) or simvastatin alone (13 events), with approximately half of these events involving hypoglycemia.<sup>1</sup> Another pharmacokinetic study conducted in 24 SLCO1B1-genotyped healthy volunteers reported that the mean AUC and Cmax of repaglinide (0.25 mg single dose) increased 18% and 41%, respectively, when coadministered with atorvastatin (40 mg once daily) in volunteers with no loss of function SLCO1B1 alleles.<sup>2</sup> In participants with 1 or 2 loss of function SLCO1B1 alleles, no changes in repaglinide AUC were seen with atorvastatin coadministration.<sup>2</sup> Atorvastatin did not significantly impact the blood glucose lowering response of repaglinide.<sup>2</sup> A third pharmacokinetic study conducted in 12 healthy Chinese males reported a mean increase in repaglinide Cmax of 15%, but no significant difference in repaglinide AUC or hypoglycemia-related adverse events when pitavastatin (4 mg once daily) was combined with repaglinide (4 mg single dose on day 5).<sup>3</sup><br><br>The mechanism of these interactions has not been fully investigated, but competition for SLCO1B1 (ie, OATP1B1) mediated hepatic uptake transport or competition for CYP3A4 metabolism may contribute. Since repaglinide is a substrate of SLCO1B1 and CYP3A4, and all statins are substrates of SLCO1B1 (and some are also substrates of CYP3A4), this interaction may apply to all statins.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. <i>J Clin Pharmacol</i>. 2003:43(6):649-660. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12817528\">[PubMed 12817528]</a></p>\n<p>2. Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. <i>Clin Pharmacol</i>. 2008:84(4):488-496. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19238654\">[PubMed 19238654]</a></p>\n<p>3. Zhu J, Song M, Tan HY, et al. Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males. <i>Pak J Pharm Sci</i>. 2013:26(3):577-584 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23625433\">[PubMed 23625433]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3564":"<p><b>Title</b> Thioridazine / CYP2D6 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP2D6 Inhibitors may increase the serum concentration of Thioridazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Thioridazine prescribing information contraindicates the concomitant use of agents that inhibit CYP2D6 isoenzymes.</p>\n<div>\n <p><b>CYP2D6 Inhibitors Interacting Members</b> Abiraterone Acetate, Asunaprevir, BuPROPion, Cinacalcet, Darifenacin, Darunavir, DULoxetine, FLUoxetine, Lorcaserin, Mirabegron, PARoxetine, Perhexiline, QuiNIDine, Rolapitant, Terbinafine (Systemic), Thioridazine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> The maximum serum concentration (Cmax) and AUC of thioridazine (25 mg single oral dose) were an average of 2.4- and 4.5-fold higher, respectively, in 6 healthy “slow hydroxylators” as compared to 13 healthy “rapid hydroxylators”.<sup>1</sup> Hydroxylation status was determined based on the speed at which these subjects metabolized debrisoquin, an agent commonly used to determine CYP2D6 enzyme activity. Similarly, thioridazine dose-corrected concentrations were 3.8- and 1.8-fold higher, respectively, in subjects who were CYP2D6 poor metabolizers (i.e., zero functional alleles) or CYP2D6 intermediate metabolizers (i.e., one functional allele) as compared to CYP2D6 extensive metabolizers (i.e., two functional alleles).<sup>2</sup> In another study of thioridazine-treated patients (n=91), thioridazine dose-corrected concentrations were also related to CYP2D6 genotype.<sup>3</sup>.<br><br>Of particular concern with higher thioridazine concentrations, thioridazine has been shown to prolong the QTc interval in a dose-dependent fashion in healthy subjects.<sup>4</sup> Compared with placebo, thioridazine increased QTc intervals by 9 msec and 23 msec with 10 mg and 50 mg doses, respectively. The degree to which elevated thioridazine concentrations secondary to altered CYP2D6 activity increases the risk for QTc prolongation and/or other toxicity is uncertain. While one study did report an association between CYP2D6 activity and QTc interval in patients receiving thioridazine monotherapy,<sup>5</sup> another study found that CYP2D6 genotype did not significantly influence on-thioridazine QTc interval.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thioridazine [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc., September 2010.</p>\n<p>2. Berecz R, de la Rubia A, Dorado P, Fernandez-Salguero P, Dahl ML, LLerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. <i>Eur J Clin Pharmacol</i>. 2003;59(1):45-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12682803\">[PubMed 12682803]</a></p>\n<p>3. Thanacoody RH, Daly AK, Reilly JG, Ferrier IN, Thomas SH. Factors affecting drug concentrations and QT interval during thioridazine therapy. <i>Clin Pharmacol Ther</i>. 2007;82(5):555-565. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17460606\">[PubMed 17460606]</a></p>\n<p>4. Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. <i>Clin Pharmacol Ther</i>. 1996;60(5):543-553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8941027\">[PubMed 8941027]</a></p>\n<p>5. LLerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. <i>J Psychopharmacol</i>. 2002;16(4):361-364. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12503836\">[PubMed 12503836]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3566":"<p><b>Title</b> Betahistine / Antihistamines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihistamines may diminish the therapeutic effect of Betahistine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effect of betahistine if coadministered with an antihistamine, particularly a blocker of histamine type-1 receptors.</p>\n<div>\n <p><b>Antihistamines Interacting Members</b> Acrivastine, Bilastine, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, Clemastine, Cyclizine, Cyproheptadine, Desloratadine, Dexbrompheniramine, Dexchlorpheniramine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Doxylamine, Ebastine, Emedastine (Systemic), Fexofenadine, HydrOXYzine, Ketotifen (Systemic), Levocetirizine, Loratadine, Meclizine, Mequitazine, Olopatadine (Systemic), Oxatomide, Oxomemazine, Pheniramine, Phenyltoloxamine, Pizotifen, Pyrilamine (Systemic), Rupatadine, Thonzylamine, Trimeprazine, Triprolidine</p>\n</div> \n<p><b>Discussion</b> Though specific data regarding this potential interaction are not available, based on the known actions of these agents, it is expected that H<sub>1</sub>-receptor antagonists may decrease the response to betahistine, an H<sub>1</sub>- and H<sub>3</sub>-receptor agonist.<sup>1</sup> H<sub>2</sub>-receptor antagonists would not be expected to interfere with betahistine activity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lacour M, Sterkers O, “Histamine and Betahistine in the Treatment of Vertigo: Elucidation of Mechanisms of Action,” <i>CNS Drugs</i>, 2001, 15(11):853-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11700150\">[PubMed 11700150]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3567":"<p><b>Title</b> Beta2-Agonists / Betahistine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Betahistine may diminish the therapeutic effect of Beta2-Agonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of beta-2 agonists if coadministered with betahistine.</p>\n<div>\n <p><b>Beta2-Agonists Interacting Members</b> Albuterol, Arformoterol, Bambuterol, Fenoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Pirbuterol, Ritodrine, Salmeterol, Terbutaline, Tulobuterol, Vilanterol</p>\n</div> \n<p><b>Discussion</b> Betahistine is a histamine H-1 agonist that may antagonize the therapeutic effects of beta-2 agonists through bronchoconstrictive or other smooth muscle effects. Prescribing information for betahistine recommends cautious use in patients with bronchial asthma irrespective of beta-2 agonist use.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Serc (betahistine dihydrochloride). Markham ON: Solvay Pharma Inc., March 2009.</p>\n<p>2. Prescribing information. Novo-betahistine (betahistine dihydrochloride tablets). Toronto, ON: Novopharm Limited, May 2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3568":"<p><b>Title</b> Potassium-Sparing Diuretics / Angiotensin II Receptor Blockers</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Routine combined use of an angiotensin converting enzyme inhibitor, angiotensin II blocker, and aldosterone antagonist such as spironolactone is not recommended for patients with heart failure with reduced ejection fraction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased risk of hyperkalemia during concomitant use of angiotensin II antagonists and potassium-sparing diuretics. Use extra caution in patients who have other potential risk factors for hyperkalemia, such as decreased renal function, diabetes, or use of other drugs that can contribute to hyperkalemia.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride, Eplerenone, Spironolactone, Triamterene</p>\n</div> \n<p><b>Discussion</b> Severe hyperkalemia with concurrent use of the angiotensin II antagonist candesartan and spironolactone, which is an aldosterone antagonist and potassium-sparing diuretic, has been reported in one published report.<sup>1</sup> Since angiotensin II antagonists can contribute to hyperkalemia and potassium-sparing diuretics also tend to increase serum potassium, their concurrent use may lead to clinically important hyperkalemia. The prescribing information of the involved drugs also caution about this potential interaction.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fujii H, Nakahama H, Yoshihara F, et al, “Life-Threatening Hyperkalemia During a Combined Therapy with the Angiotensin Receptor Blocker Candesartan and Spironolactone,” <i>Kobe J Med Sci</i>, 2005, 51(1-2):1-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16199929\">[PubMed 16199929]</a></p>\n<p>2. Prescribing information. Aldactone (spironolactone). New York, NY: Pfizer Inc, January 2008.</p>\n<p>3. Prescribing information. Amiloride and Hydrochlorothiazide. Morgantown, WV: Mylan Pharmaceuticals Inc., March 2003.</p>\n<p>4. Prescribing information. Dyazide (hydrochlorothiazide and triamterene). Research Triangle Park, NC: GlaxoSmithKline, February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3569":"<p><b>Title</b> Angiotensin II Receptor Blockers / Potassium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of hyperkalemia during concomitant use of angiotensin II antagonists and potassium supplements.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n <p><b>Potassium Salts Interacting Members</b> Potassium Acetate, Potassium Chloride, Potassium Citrate, Potassium Gluconate, Potassium Iodate, Potassium Iodide, Potassium Phosphate</p>\n</div> \n<p><b>Discussion</b> The use of potassium supplements or potassium-containing salt substitutes by patients receiving angiotensin II antagonists may increase the risk of developing hyperkalemia.<sup>1</sup><br><br>This interaction is most likely the result of aldosterone suppression in patients receiving angiotensin II receptor antagonists, which may increase potassium retention.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cozaar (losartan potassium). Whitehouse Station, NJ: Merck &amp; Co, Inc, December 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3571":"<p><b>Title</b> CYP2A6 Substrates (High risk with Inducers) / CYP2A6 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2A6 Inducers (Strong) may increase the metabolism of CYP2A6 Substrates (High risk with Inducers). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative for one of the interacting drugs in order to avoid therapeutic failure of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for decreased effects of the CYP substrate if a CYP inducer is initiated/dose increased, and increased effects if a CYP inducer is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2A6 Inducers (Strong) Interacting Members</b> Amobarbital, HYDROXYprogesterone Caproate, PENTobarbital, PHENobarbital, RifAMPin, Secobarbital</p>\n <p><b>CYP2A6 Substrates (High risk with Inducers) Interacting Members</b> Artesunate, Tegafur</p>\n</div> \n<p><b>Discussion</b> The CYP inducers in this monograph will probably increase the metabolism of the substrates of this pathway. Substrate clearance would increase and serum concentrations would decrease. Decreased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant decrease in serum concentration of the substrate (ie, &gt;50%) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inducers have been labeled “strong” because they have been shown to cause significant increases in CYP activity, and, therefore, significant increases in the clearance of drugs metabolized by this pathway.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p>2. U.S. Food and Drug Administration, “Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and LabelingRecommendations,” http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf (accessed March 18, 2013).</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3573":"<p><b>Title</b> CYP2C19 Substrates (High risk with Inducers) / CYP2C19 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates (High risk with Inducers). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative for one of the interacting drugs in order to avoid therapeutic failure of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for decreased effects of the CYP substrate if a CYP inducer is initiated/dose increased, and increased effects if a CYP inducer is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP2C19 Inducers (Strong) Interacting Members</b> Apalutamide, RifAMPin</p>\n <p><b>CYP2C19 Substrates (High risk with Inducers) Interacting Members</b> Bortezomib, Brivaracetam, Carisoprodol, Citalopram, CloBAZam, ClomiPRAMINE, Desogestrel, DiazePAM, Dydrogesterone, Escitalopram, Esomeprazole, Etizolam, Etravirine, Fosphenytoin, Imipramine, Lansoprazole, Methsuximide, Moclobemide, Nelfinavir, Nilutamide, Omeprazole, Pantoprazole, PHENobarbital, Phenytoin, Progesterone, RABEprazole, Stiripentol, Trimipramine, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The CYP inducers in this monograph will probably increase the metabolism of the substrates of this pathway. Substrate clearance would increase and serum concentrations would decrease. Decreased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant decrease in serum concentration of the substrate (ie, &gt;50%) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inducers have been labeled “strong” because they have been shown to cause significant increases in CYP activity, and, therefore, significant increases in the clearance of drugs metabolized by this pathway.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p>2. U.S. Food and Drug Administration, “Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and LabelingRecommendations,” http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf (accessed March 18, 2013).</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3574":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inducers) / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates (High risk with Inducers). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider an alternative for one of the interacting drugs in order to avoid therapeutic failure of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for decreased effects of the CYP substrate if a CYP inducer is initiated/dose increased, and increased effects if a CYP inducer is discontinued/dose decreased.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n <p><b>CYP3A4 Substrates (High risk with Inducers) Interacting Members</b> Abemaciclib, Abiraterone Acetate, Acalabrutinib, Alfuzosin, ALPRAZolam, Amiodarone, AmLODIPine, Apixaban, Apremilast, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Armodafinil, Artemether, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Bedaquiline, Benidipine, Benzphetamine, Bisoprolol, Blonanserin, Boceprevir, Bortezomib, Bosutinib, Brexpiprazole, Brigatinib, Bromperidol, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Citalopram, Clarithromycin, ClonazePAM, Clorazepate, Cobicistat, Cobimetinib, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Daclatasvir, Dantrolene, Dapsone (Systemic), Darifenacin, Darunavir, Dasabuvir, Dasatinib, Deflazacort, Delavirdine, Dexamethasone (Systemic), DiazePAM, Dienogest, Digitoxin, DilTIAZem, Disopyramide, DOCEtaxel, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Efavirenz, Elbasvir, Eliglustat, Elvitegravir, Enzalutamide, Eplerenone, Erlotinib, Erythromycin (Systemic), Escitalopram, Estradiol (Systemic), Estradiol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Eszopiclone, Ethinyl Estradiol, Ethosuximide, Etoposide, Etoposide Phosphate, Etoricoxib, Etravirine, Everolimus, Exemestane, Felbamate, Felodipine, Fesoterodine, Flibanserin, Flurazepam, Fosamprenavir, Fosaprepitant, Gefitinib, Gemigliptin, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROXYprogesterone Caproate, Ibrutinib, Idelalisib, Imatinib, Indinavir, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ixazomib, Ketoconazole (Systemic), Lacidipine, Lansoprazole, Lapatinib, Lercanidipine, Levonorgestrel (Systemic), Lidocaine (Systemic), Linagliptin, Lomitapide, Losartan, Lovastatin, Lumefantrine, Lurasidone, Lynestrenol, Macimorelin, Macitentan, Manidipine, Maraviroc, MedroxyPROGESTERone, Mefloquine, Mestranol, Methadone, Mianserin, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Modafinil, Naldemedine, Naloxegol, Nefazodone, Nelfinavir, Neratinib, Netupitant, Nevirapine, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Norethindrone, Norgestrel, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Ondansetron, Osimertinib, Ospemifene, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Perampanel, Pimozide, Piperaquine, Pipotiazine, Praziquantel, Primaquine, Progesterone, QUEtiapine, QuiNIDine, QuiNINE, RABEprazole, Radotinib, Ranolazine, Regorafenib, Repaglinide, Ribociclib, Rifabutin, Rilpivirine, Riociguat, Ritonavir, Rivaroxaban, Roflumilast, Rolapitant, RomiDEPsin, Saquinavir, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tamoxifen, Tamsulosin, Tasimelteon, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tetracycline (Systemic), Tezacaftor, TiaGABine, Tibolone, Ticagrelor, Ticlopidine, Tipranavir, Tofacitinib, Tolterodine, Tolvaptan, Toremifene, Trabectedin, TraMADol, TraZODone, Triazolam, Trimethoprim, Trimipramine, Ulipristal, Valbenazine, Vandetanib, Velpatasvir, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, Vilazodone, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vortioxetine, Voxilaprevir, Zonisamide, Zopiclone<br><b>Exceptions</b> Benzhydrocodone, Buprenorphine, Etizolam, HYDROcodone, Zolpidem</p>\n</div> \n<p><b>Discussion</b> The CYP inducers in this monograph will probably increase the metabolism of the substrates of this pathway. Substrate clearance would increase and serum concentrations would decrease. Decreased effects of the substrates would be expected.<br><br>CYP substrates have been included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant decrease in serum concentration of the substrate (ie, &gt;50%) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inducers have been labeled “strong” because they have been shown to cause significant increases in CYP activity, and, therefore, significant increases in the clearance of drugs metabolized by this pathway.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al, “The Conduct of <i>In Vitro</i> and <i>In Vivo</i> Drug-Drug Interaction Studies: A PhRMA Perspective,” <i>J Clin Pharmacol</i>, 2003, 43(5):443-69. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p>2. U.S. Food and Drug Administration, “Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and LabelingRecommendations,” http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf (accessed March 18, 2013).</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3575":"<p><b>Title</b> Neuromuscular-Blocking Agents (Nondepolarizing) / Trimebutine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimebutine may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased neuromuscular-blocking effects if a nondepolarizing neuromuscular-blocking agent is used in a patient receiving trimebutine.</p>\n<div>\n <p><b>Neuromuscular-Blocking Agents (Nondepolarizing) Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Vecuronium</p>\n</div> \n<p><b>Discussion</b> The manufacturer of trimebutine reports that the duration of action of tubocurarine was increased by trimebutine in animal studies.<sup>1</sup><br><br>The mechanism of any interaction between trimebutine and nondepolarizing neuromuscular-blocking agents is unclear. Confirmatory data in humans are lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Modulon (trimebutine) [product monograph]. Mont-Saint-Hilaire, Quebec, Canada: Aptalis Pharma Canada, Inc.; November 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3578":"<p><b>Title</b> Vaccines (Live) / Immunosuppressants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The clinical significance of this interaction may be somewhat lower with low doses of certain immunosuppressant medications.</p></li>\n <li><p><b>Duration</b>: The clinical significance of this interaction may be somewhat lower with shorter duration of exposure to systemic corticosteroids.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Whenever possible, patients should receive all recommended vaccinations prior to initiation of immunosuppressant therapy. Live vaccine administration should generally be avoided in patients with impaired immune function due to the risk of developing a clinical infection from the live vaccine. Inadequate immune response to the vaccine may also occur in the presence of immunosuppressants. Live vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy unless the benefit of vaccine administration outweighs the potential risk. Infliximab labeling also specifies that infants exposed to infliximab in utero should not receive live vaccines for at least 6 months after birth. The risk of clinically significant immunosuppression is considered likely to be dose- and drug-dependent. <br><br>Note that some products (e.g., both seasonal and H1N1 influenza virus vaccines) are available as either a live or inactivated product; this interaction pertains only to the live form of these vaccines.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, Basiliximab, Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine<br><b>Exceptions</b> AzaTHIOprine, Beclomethasone (Oral Inhalation), Betamethasone (Systemic), Budesonide (Systemic), Corticotropin, Cortisone, Cytarabine (Liposomal), Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Fluticasone (Oral Inhalation), Hydrocortisone (Systemic), Leflunomide, Mercaptopurine, Methotrexate, MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> A case report describes a patient who developed a vaccinial infection due to smallpox vaccine when administered while under treatment with methotrexate (15 mg/day) for psoriasis.<sup>1</sup> Animals studies have confirmed the increased susceptibility to vaccinial infections when receiving immunosuppressants.<sup>2</sup> Other reports of severe complications following administration of live vaccines to patients with disease-related compromised immune function further emphasize this potential risk.<sup>3,4,5,6,7,8,9,10,11</sup> While receiving immunosuppressant agents, patients may lack adequate protection against the live organism vaccine.<br><br>General recommendations of the Advisory Committee on Immunization Practices (ACIP) states that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy.<sup>12</sup> According to these recommendations, all persons receiving chemotherapy or radiation for leukemia or other hematopoetic malignancies, solid tumors, or after solid organ transplantation should be considered to be potentially immunosuppressed. Additionally, the recommendations state that live vaccines should even be avoided with low-dose and/or intermittent use of immunosuppressant drugs unless the potential benefit outweighs the risk.<sup>12</sup><br><br>Of note, ACIP recommendations acknowledge that the risk of clinically significant immunosuppression is likely dose- and drug-dependent.<sup>12</sup> Consistent with this factor, the American College of Rheumatology specifically does not recommend avoiding live vaccines in patients being treated with hydroxychloroquine, leflunomide, or methotrexate.<sup>13</sup> Similarly, the ACIP recommendations on the prevention of Herpes Zoster state that therapy with low-doses of methotrexate (0.4 mg/kg/week or less), azathioprine (3.0 mg/kg/day or less), or 6-mercaptopurine (1.5 mg/kg/day or less) are not sufficiently immunosuppressive to create safety concerns and are not contraindications for administration of the zoster vaccine.<sup>14</sup> Systemic corticosteroids also appear subject to dose- and duration-dependency regarding their immunosuppressant effects.<sup>12</sup> With regard to systemic corticosteroids, doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered sufficiently immunosuppressive to warrant concern about the safety of coadministered live organism vaccines. Providers should wait at least 1 month after cessation of systemic corticosteroids (at doses greater than or equivalent to those described above) before administering a live-attenuated vaccine.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Allison J, “Methotrexate and Smallpox Vaccination,” <i>Lancet</i>, 1968, ii:1250. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4177233\">[PubMed 4177233]</a></p>\n<p>2. Rosenbaum EH, Cohen RA, and Glatstein HR, “Vaccination of a Patient Receiving Immunosuppressive Therapy for Lymphosarcoma,” <i>JAMA</i>, 1966, 198:737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5953328\">[PubMed 5953328]</a></p>\n<p>3. Sixbey JW, “Routine Immunization of the Immunocompromised Child,” <i>Adv Pediatr Infect Dis</i>, 1987, 2:79-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3331284\">[PubMed 3331284]</a></p>\n<p>4. Wright PF, Hatch MH, Kasselberg AG, et al, “Vaccine-Associated Poliomyelitis in a Child with Sex-Linked Agammaglobulinemia,” <i>J Pediatr</i>, 1977, 91:408-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=197220\">[PubMed 197220]</a></p>\n<p>5. Wyatt HV, “Poliomyelitis in Hypogammaglobulinemics,” <i>J Infect Dis</i>, 1973, 128:802-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4765357\">[PubMed 4765357]</a></p>\n<p>6. Davis LE, Bodian D, Price D, et al, “Chronic Progressive Poliomyelitis Secondary to Vaccination of an Immunodeficient Child,” <i>N Engl J Med</i>, 1977, 297:241-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=195206\">[PubMed 195206]</a></p>\n<p>7. CDC, “Disseminated Mycobacterium bovis Infection from BCG Vaccination of a Patient with Acquired Immunodeficiency Syndrome,” <i>MMWR</i>, 1985, 34:227-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3920493\">[PubMed 3920493]</a></p>\n<p>8. Ninane J, Grymonprez A, Burtonboy G, et al, “Disseminated BCG in HIV Infection,” <i>Arch Dis Child</i>, 1988, 63:1268-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3196057\">[PubMed 3196057]</a></p>\n<p>9. Redfield RR, Wright DC, James WD, et al, “Disseminated Vaccinia in a Military Recruit with Human Immunodeficiency Virus (HIV) Disease,” <i>N Engl J Med</i>, 1987, 316:673-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3821799\">[PubMed 3821799]</a></p>\n<p>10. CDC, “Measles Pneumonitis Following Measles-Mumps-Rubella Vaccination of a Patient with HIV Infection, 1993,” <i>MMWR</i>, 1996, 45:603-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8676852\">[PubMed 8676852]</a></p>\n<p>11. Costa E, Buxton J, Brown J, Templeton KE, Breuer J, Johannessen I. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient [published online May 4, 2016]. <i>BMJ Case Rep</i>. doi: 10.1136/bcr-2015-212688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27147629\">[PubMed 27147629]</a></p>\n<p>12. Kroger AT, Atkinson WL, Marcuse EK, et al, “General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR</i>, 2006, 55(RR-15):1-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17136024\">[PubMed 17136024]</a></p>\n<p>13. Saag KG, Teng GG, Patkar NM, et al, “American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis,” <i>Arthritis Rheum</i>, 2008, 59(6):762-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18512708\">[PubMed 18512708]</a></p>\n<p>14. Harpaz R, Ortega-Sanchez IR, Seward JF, et al, “Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP),” <i>MMWR Recomm Rep</i>, 2008, 57(RR-5):1-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18528318\">[PubMed 18528318]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3579":"<p><b>Title</b> Immunosuppressants / Echinacea</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Echinacea may diminish the therapeutic effect of Immunosuppressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Echinacea should be used with caution, if at all, in patients receiving therapeutic immunosuppressants. Monitor for reduced efficacy of the immunosuppressant during concomitant use.</p>\n<div>\n <p><b>Immunosuppressants Interacting Members</b> Abatacept, Abemaciclib, Acalabrutinib, Adalimumab, Ado-Trastuzumab Emtansine, Alemtuzumab, Altretamine, Amsacrine, Anakinra, Antithymocyte Globulin (Equine), Antithymocyte Globulin (Rabbit), AzaCITIDine, AzaTHIOprine, Basiliximab, Beclomethasone (Oral Inhalation), Beclomethasone (Systemic), Belatacept, Belimumab, Belotecan, Betamethasone (Systemic), Bleomycin, Blinatumomab, Brentuximab Vedotin, Brodalumab, Budesonide (Systemic), Busulfan, Cabazitaxel, Canakinumab, Capecitabine, CARBOplatin, Carmustine, Certolizumab Pegol, Chlorambucil, CISplatin, Cladribine, Clofarabine, Copanlisib, Corticotropin, Cortisone, Cyclophosphamide, CycloSPORINE (Systemic), Cytarabine (Conventional), Dacarbazine, Daclizumab, DACTINomycin, Dasatinib, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Deflazacort, Dexamethasone (Systemic), Dinutuximab, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Eculizumab, Elotuzumab, EpiRUBicin, Estramustine, Etanercept, Etoposide, Etoposide Phosphate, Everolimus, Fingolimod, Floxuridine, Fludarabine, Fludrocortisone, Fluorouracil (Systemic), Fluticasone (Oral Inhalation), Fotemustine, Gemcitabine, Gemtuzumab Ozogamicin, Glatiramer Acetate, Golimumab, Guselkumab, Hydrocortisone (Systemic), Hydroxyurea, Ibritumomab Tiuxetan, Ibrutinib, IDArubicin, Idelalisib, Ifosfamide, Imatinib, Imiquimod, InFLIXimab, Inotuzumab Ozogamicin, Irinotecan (Conventional), Irinotecan (Liposomal), Ixekizumab, Leflunomide, Lenalidomide, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MethylPREDNISolone, MitoMYcin (Systemic), MitoXANTRONE, Mizoribine, Mycophenolate, Natalizumab, Nelarabine, Nilotinib, Obinutuzumab, Ocrelizumab, Ofatumumab, Omacetaxine, Osimertinib, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pegaspargase, PEMEtrexed, Pentostatin, Pixantrone, Pomalidomide, PRALAtrexate, PrednisoLONE (Systemic), PredniSONE, Procarbazine, Ribociclib, Rilonacept, RiTUXimab, RomiDEPsin, Ruxolitinib, Sarilumab, Secukinumab, Siltuximab, Sirolimus, SORAfenib, Streptozocin, SUNItinib, Tacrolimus (Systemic), Tegafur, Temozolomide, Temsirolimus, Teniposide, Teriflunomide, Thalidomide, Thioguanine, Thiotepa, Tocilizumab, Tofacitinib, Topotecan, Trabectedin, Treosulfan, Tretinoin (Systemic), Triamcinolone (Systemic), Trifluridine and Tipiracil, Ustekinumab, Vedolizumab, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine<br><b>Exception</b> Cytarabine (Liposomal)</p>\n</div> \n<p><b>Discussion</b> Echinacea is reported to possess immunostimulatory activity demonstrated by activation of macrophages (releasing interleukin-1), and proliferation of B-lymphocytes.<sup>1,2</sup> Such activity may, theoretically, oppose the therapeutic intentions of various immunosuppressants.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stimpel M, Proksch A, Wagner H, et al, “Macrophage Activation and Induction of Macrophage Cytotoxicity by Purified Polysaccharide Fractions From the Plant Echinacea Purpurea,” <i>Infect Immun</i>, 1984, 46(3):845-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6389368\">[PubMed 6389368]</a></p>\n<p>2. Luettig B, Steinmuller C, Gifford GE, et al, “Macrophage Activation by the Polysaccharide Arabinogalactan Isolated From Plant Cell Cultures of Echinacea Purpurea,” <i>J Natl Cancer Inst</i>, 1989, 81(9):669-75. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2785214\">[PubMed 2785214]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3581":"<p><b>Title</b> Ezetimibe / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the absorption of Ezetimibe. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer ezetimibe at least 2 hours before or 4 hours after any bile acid sequestrant.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam, Colestipol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Ezetimibe prescribing information recommends administration at least 2 hours before or 4 hours after any bile acid sequestrant, to minimize the potential for bile acid sequestrants to bind to ezetimibe in the gastrointestinal tract and inhibit its absorption.<sup>1</sup> In a clinical study, the AUC of ezetimibe was decreased 55% in 40 patients when coadministered with cholestyramine (4 g twice daily).<sup>1</sup> <br><br>The impact of the manufacturer's recommended dose scheduling has not been systematically studied. In one small clinical study, similar LDL-lowering effects were seen with ezetimibe administered simultaneously with colesevelam (n=8) or an average of 1.7 hours prior (n=4).<sup>2</sup> Several additional reports also describe good clinical responses to ezetimibe in combination with bile acid sequestrants when dosed separately, although the specific dose spacing is typically not well-defined in these reports.<sup>3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zetia (ezetimibe). Whitehouse Station, NJ: Merck &amp; Co., Inc., 2/2013.</p>\n<p>2. Zema MJ, “Colesevelam HCl and Ezetimibe Combination Therapy Provides Effective Lipid-Lowering in Difficult-to-Treat Patients With Hypercholesterolemia,” <i>Am J Ther</i>, 2005, 12(4):306-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16041193\">[PubMed 16041193]</a></p>\n<p>3. Salen G, Starc T, Sisk CM, et al, “Intestinal Cholesterol Absorption Inhibitor Ezetimibe Added to Cholestyramine for Sitosterolemia and Xanthomatosis,” <i>Gastroenterology</i>, 2006, 130(6):1853-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16697747\">[PubMed 16697747]</a></p>\n<p>4. Knopp RH, Tsunehara C, Retzlaff BM, et al, “Lipoprotein Effects of Combined Ezetimibe and Colesevelam Hydrochloride Versus Ezetimibe Alone in Hypercholesterolemic Subjects: A Pilot Study,” <i>Metabolism</i>, 2006, 55(12):1697-703. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17142146\">[PubMed 17142146]</a></p>\n<p>5. Huijgen R, Abbink EJ, Bruckert E, et al, “Colesevelam Added to Combination Therapy With a Statin and Ezetimibe in Patients With Familial Hypercholesterolemia: A 12-Week, Multicenter, Randomized, Double-Blind, Controlled Trial,” <i>Clin Ther</i>, 2010, 32(4):615-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20435231\">[PubMed 20435231]</a></p>\n<p>6. Bays H, Rhyne J, Abby S, et al, “Lipid-Lowering Effects of Colesevelam HCl in Combination With Ezetimibe,” <i>Curr Med Res Opin</i>, 2006, 22(11):2191-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17076980\">[PubMed 17076980]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3584":"<p><b>Title</b> Eplerenone / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Eplerenone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Reduce the starting dose of eplerenone to 25 mg/day when being used in a patient who is also being treated with fluconazole. Monitor patients closely for increased eplerenone effects while using the combination. Also monitor patients for signs/symptoms of decreased eplerenone effects if fluconazole is discontinued or if the fluconazole dose is reduced.</p> \n<p><b>Discussion</b> The AUC of eplerenone was increased an average of 2.24-fold when coadministered with fluconazole 200 mg daily.<sup>1,2</sup> The magnitude of this interaction is consistent with what was predicted based on both the calculated Ki of fluconazole for eplerenone 6-beta-hydroxylation and the maximum fluconazole serum concentration.<sup>2</sup><br><br>Eplerenone metabolism is primarily mediated by CYP3A4, and it is suspected that fluconazole, a moderate CYP3A4 inhibitor, interacts by inhibiting the CYP3A-mediated metabolism of eplerenone.<sup>1,2</sup> Eplerenone prescribing information recommends that the starting dose of eplerenone be reduced to 25 mg/day when being used in someone who is also receiving any moderate CYP3A4 inhibitor.<sup>1</sup> Concurrent use with any strong CYP3A4 inhibitors is contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Inspra (eplerenone). New York, NY: Pfizer Inc, APR 2008.</p>\n<p>2. Cook CS, Berry LM, Burton E, “Prediction of In Vivo Drug Interactions with Eplerenone in Man from In Vitro Metabolic Inhibition Data,” <i>Xenobiotica</i>, 2004, 34(3):215-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15204695\">[PubMed 15204695]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3586":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Eplerenone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Routine combined use of an angiotensin converting enzyme inhibitor, angiotensin II blocker, and aldosterone antagonist such as eplerenone is not recommended for patients with heart failure with reduced ejection fraction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Eplerenone may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased incidence of hyperkalemia during concomitant use of eplerenone and angiotensin-converting enzyme inhibitors.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> The incidence of hyperkalemia (serum potassium &gt; 5.5 mEq/L) was 38% during concomitant therapy with eplerenone (200 mg/day) and enalapril (10 mg/day), while only 17% during therapy with enalapril alone in a study of diabetics with microalbuminuria.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Inspra [package insert]. Chicago, IL: Pharmacia Corporation, 2002.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3587":"<p><b>Title</b> Angiotensin II Receptor Blockers / Eplerenone</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Routine combined use of an angiotensin converting enzyme inhibitor, angiotensin II blocker, and aldosterone antagonist such as eplerenone is not recommended for patients with heart failure with reduced ejection fraction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Eplerenone may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased incidence of hyperkalemia during concomitant use of eplerenone and angiotensin II antagonists.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n</div> \n<p><b>Discussion</b> The incidence of hyperkalemia (serum potassium &gt; 5.5 mEq/L) was 38% during concomitant therapy with eplerenone (200 mg/day) and enalapril (10 mg/day), while only 17% during therapy with enalapril alone in a study of diabetics with microalbuminemia.<sup>1</sup> Caution should be employed with angiotensin II antagonists as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Inspra [package insert]. Chicago, IL: Pharmacia Corporation, 2002.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3588":"<p><b>Title</b> Mirtazapine / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the neurotoxic (central) effect of Mirtazapine. While methylene blue and linezolid are expected to interact, specific recommendations for their use differ from other monoamine oxidase inhibitors. Refer to monographs specific to those agents for details. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of mirtazapine with a monoamine oxidase inhibitor (MAOI) is contraindicated. Similarly, both the use of mirtazapine within 14 days of stopping a MAOI and the use of a MAOI within 14 days of stopping mirtazapine are also contraindicated. This contraindication does extend to agents such as linezolid and methylene blue, which do also possess MAOI activity.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tranylcypromine<br><b>Exceptions</b> Linezolid, Methylene Blue, Tedizolid</p>\n</div> \n<p><b>Discussion</b> According to the mirtazapine prescribing information, concurrent use with a monoamine oxidase inhibitor (MAOI) is contraindicated, as is both the use of mirtazapine within 14 days of stopping a MAOI and the use of a MAOI within 14 days of stopping mirtazapine.<sup>1</sup> Use of these agents together may result in serotonin syndrome, which is the basis for this labeled contraindication. This risk does extend to agents such as linezolid and methylene blue, which do also possess MAOI activity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Remeron (mirtazapine). Whitehouse Station, NJ: Merck &amp; Co., Inc., 10/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3589":"<p><b>Title</b> BuPROPion / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the hypertensive effect of BuPROPion. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The use of monoamine oxidase inhibitors intended to treat psychiatric disorders and bupropion, concomitantly or within 14 days of each other, is considered contraindicated. Initiation of bupropion is considered contraindicated during treatment with linezolid or methylene blue, although initiation of linezolid or methylene blue in a bupropion-treated patient could be considered if the expected benefit of treatment outweighs the potential risks (in light of therapeutic alternatives) and bupropion is discontinued. Under these circumstances, monitor for hypertensive reactions for the first 14 days after bupropion discontinuation, or until 24 hours after the last dose of linezolid or methylene blue, whichever comes first. Suspended bupropion treatment may be resumed 24 hours after the last dose of linezolid or methylene blue.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The manufacturer of bupropion warns that concomitant use with a monoamine oxidase inhibitor may increase the risk of hypertensive reactions, and that animal studies demonstrate that concomitant administration with the monoamine oxidase inhibitor (MAOI) phenelzine results in increased bupropion toxicity.<sup>1</sup> Published case reports variably describe patients who did<sup>2</sup> or did not<sup>3,4,5,6</sup> develop signs or symptoms of such toxicity during treatment with these combinations. <br><br>These interactions are presumed to result from the combined dopamine and norepinephrine potentiating effects of bupropion and monoamine oxidase inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Wellbutrin (bupropion). Research Triangle Park, NC: Glaxo Wellcome Inc, March 2013.</p>\n<p>2. Marcucci C, Sandson NB and Dunlap JA, “Linezolid-Bupropion Interaction as Possible Etiology of Severe Intermittent Intraoperative Hypertension?” <i>Anesthesiology</i>, 2004, 101(6):1487-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15564978\">[PubMed 15564978]</a></p>\n<p>3. Kaur N, Madan R and Sharma A, “Successful Use of Rasagiline in Combination With Two Antidepressants: A Case Report,” <i>Innov Clin Neurosci</i>, 2012, 9(11-12):39-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23346517\">[PubMed 23346517]</a></p>\n<p>4. Quante A and Zeugmann S, “Tranylcypromine and Bupropion Combination Therapy in Treatment-Resistant Major Depression: A Report of 2 Cases,” <i>J Clin Psychopharmacol</i>, 2012, 32(4):572-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22760351\">[PubMed 22760351]</a></p>\n<p>5. Pierre JM and Gitlin MJ, “Bupropion-Tranylcypromine Combination for Treatment-Refractory Depression,” <i>J Clin Psychiatry</i>, 2000, 61(6):450-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10901349\">[PubMed 10901349]</a></p>\n<p>6. Ritter JL and Alexander B, “Retrospective Study of Selegiline-Antidepressant Drug Interactions and a Review of the Literature,” <i>Ann Clin Psychiatry</i>, 1997, 9(1):7-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9167831\">[PubMed 9167831]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3590":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Potassium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of hyperkalemia during concomitant use of angiotensin-converting enzyme inhibitors and potassium supplements.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p><b>Potassium Salts Interacting Members</b> Potassium Acetate, Potassium Chloride, Potassium Citrate, Potassium Gluconate, Potassium Iodate, Potassium Iodide, Potassium Phosphate</p>\n</div> \n<p><b>Discussion</b> The use of potassium supplements or potassium-containing salt substitutes by patients receiving angiotensin-converting enzyme inhibitors may increase the risk of developing hyperkalemia.<sup>1,2</sup> The risk is likely greater in patients with additional risk factors for the development of hyperkalemia (eg, renal insufficiency, use of potassium-sparing diuretics).<sup>1</sup><br><br>This interaction is most likely the result of aldosterone suppression in patients receiving angiotensin-converting enzyme inhibitors, which may increase potassium retention.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zestril</i> (lisinopril) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2014.</p>\n<p>2. Burnakis TG, Mioduch HJ. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia. <i>Arch Intern Med</i>. 1984;144(12):2371-2372. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6391404\">[PubMed 6391404]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3591":"<p><b>Title</b> Dihydrocodeine / QuiNIDine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> QuiNIDine may diminish the analgesic effect of Dihydrocodeine. Specifically, quinidine may prevent the metabolic conversion of dihydrocodeine to its active metabolite <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased analgesic effects in patients taking dihydrocodeine and quinidine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 17 extensive CYP2D6 metabolizers, administration of dihydrocodeine (60 mg single dose) 2 hours after administration of quinidine (50 mg single dose) reduced the urinary recovery of dihydromorphine (an active metabolite of dihydrocodeine) 3.4-fold.<sup>1</sup> The ratio of dihydrocodeine to dihydromorphine recovered in the urine was reduced 3-fold.<sup>1</sup> In another study of 10 extensive CYP2D6 metabolizers, concomitant administration of dihydrocodeine (60 mg single dose) and quinidine (50 mg single dose) reduced the urinary excretion of dihydromorphine 3.25-fold.<sup>2</sup> Plasma concentrations of dihydromorphine were reduced (between 3- and 4-fold) with quinidine coadministration, while plasma concentrations of dihydrocodeine remained unchanged.<sup>2</sup> Quinidine did not change the effects of dihydrocodeine on pain thresholds, but did decrease its effect on defecatory urge thresholds.<sup>2</sup><br><br>The mechanism of this interaction is likely the result of quinidine inhibition of CYP2D6, an enzyme responsible for conversion of dihydrocodeine to an active metabolite dihydromorphine. The contribution of dihydromorphine to the overall analgesic effect of dihydrocodeine is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hufschmid E, Theurillat R, Wilder-Smith CH, Thormann W. Characterization of the genetic polymorphism of dihydrocodeine O-demethylation in man via analysis of urinary dihydrocodeine and dihydromorphine by micellar electrokinetic capillary chromatography. <i>J Chromatog B Biomed Appl</i>. 1996;678(1):43-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8861655\">[PubMed 8861655]</a></p>\n<p>2. Wilder-Smith C H, Hufschmid, E, Thormann W. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizers. <i>Br J Clin Pharmacol</i>. 1998;45(6):575-581. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9663813\">[PubMed 9663813]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3592":"<p><b>Title</b> Cardiac Glycosides / Teriparatide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Teriparatide may enhance the adverse/toxic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the low risk for a clinically significant interaction, no specific action is needed.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> Single-dose teriparatide (20 mcg subcutaneously) administered to 15 healthy subjects who had been taking digoxin for 13 days (dosed to achieve and maintain a steady-state digoxin concentration of 1-2 ng/mL) did not significantly alter the calcium-mediated pharmacodynamic response to digoxin (i.e., systolic time interval).<sup>1</sup><br><br>Due to concerns that hypercalcemia produced by teriparatide could predispose cardiac glycoside-receiving patients to enhanced (toxic) cardiac effects, teriparatide product labeling recommends caution when using teriparatide in patients receiving digoxin or other cardiac glycosides.<sup>2</sup> Teriparatide causes a transient increase in serum calcium that peaks at 4-6 hours after dosing, with a return to baseline calcium after 16-24 hours.<sup>2</sup> In studies described in the prescribing information, approximately 6-11% of patients receiving teriparatide had at least one measured serum calcium concentration that exceeded the upper limit of normal, but measured calcium concentrations were only rarely elevated for two or more consecutive tests.<sup>2</sup> Additionally, the clinical significance of mild and/or transient calcium elevations on digoxin toxicity is unclear, as data indicate that a significant digoxin-calcium interaction requires considerably high concentrations of digoxin and/or calcium.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Benson CT, Voelker JR, “Teriparatide Has No Effect on the Calcium-Mediated Pharmacodynamics of Digoxin,” <i>Clin Pharmacol Ther</i>, 2003, 73:87-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12545147\">[PubMed 12545147]</a></p>\n<p>2. Prescribing information. Forteo (teriparatide). Indianapolis, IN: Eli Lilly and Company, February 2008.</p>\n<p>3. Nola GT, Pope S, Harrison DC, “Assessment of the Synergistic Relationship between Serum Calcium and Digitalis,” <i>Am Heart J</i>, 1970, 79:499-507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5418023\">[PubMed 5418023]</a></p>\n<p>4. Lown B, Black H, Moore FD, “Digitalis, Electrolytes and the Surgical Patient,” <i>Am J Cardiol</i>, 1960, 6:309-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14418577\">[PubMed 14418577]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3593":"<p><b>Title</b> Beta2-Agonists / AtoMOXetine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> AtoMOXetine may enhance the tachycardic effect of Beta2-Agonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased cardiovascular effects of beta<sub>2</sub>-agonists (eg, tachycardia, hypertension) if used concomitant with atomoxetine.</p>\n<div>\n <p><b>Beta2-Agonists Interacting Members</b> Albuterol, Arformoterol, Bambuterol, Fenoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Pirbuterol, Ritodrine, Salmeterol, Terbutaline, Tulobuterol, Vilanterol</p>\n</div> \n<p><b>Discussion</b> The tachycardic and hypertensive effects of albuterol (600 mcg IV over 2 hours) were potentiated following a 5-day course of atomoxetine (60 mg twice daily).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company, 2002.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3594":"<p><b>Title</b> AtoMOXetine / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Atomoxetine should not be used within 14 days of a monoamine oxidase inhibitor. Concomitant use could result in serious central nervous system effects (eg, nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability with rapid fluctuations of vital signs, seizures, and mental status changes ranging from agitation to coma). Monitor for such events.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> As an effector of brain monoamine concentrations, concomitant use with a monoamine oxidase inhibitor (MAOI) should be avoided. The manufacturer notes that concomitant use of an MAOI and other similar drugs have produced serious, even fatal, events including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Strattera (atomoxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3595":"<p><b>Title</b> Cardiac Glycosides / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of thiazide diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased cardiac glycoside toxicity (eg, cardiac arrhythmias) if a thiazide diuretic is initiated or the dose is increased. Careful monitoring of serum potassium and magnesium along with administration of electrolyte replacement therapy to correct hypokalemia or hypomagnesemia may reduce the risk of cardiac glycoside toxicity.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> The risk of cardiac glycoside toxicity increases in the presence hypokalemia and hypomagnesemia, even when serum concentrations are maintained in the therapeutic range.<sup>1</sup> The association of digitalis toxicity and electrolyte disturbances induced by diuretic (loop and thiazide) use has been reported in numerous studies<sup>2,3,4,5,6,7,8</sup> and case reports<sup>9,10</sup> In contrast, some studies report that serum potassium levels do not influence the risk of digitalis toxicity,<sup>11,12,13</sup> possibly because serum potassium concentrations may not correlate with total body potassium stores.<br><br>Prescribing information for digoxin recommends careful monitoring of serum potassium and magnesium levels in patients receiving digoxin along with diuretics.<sup>1</sup> Administering electrolyte replacement to correct hypokalemia and hypomagnesemia is recommended.<br><br>Cardiac glycosides and potassium compete for binding to the cardiac sodium-potassium ATP pump (Na-K-ATPase). It is proposed that in the presence of hypokalemia, the reduced competition for the Na-K-ATPase allows for more cardiac glycoside binding and effects. Further binding of the glycoside to the Na-K-ATPase reduces intracellular potassium, which is thought to increase the risk of cardiac glycoside toxicity.<sup>14</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digoxin [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2012.</p>\n<p>2. Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalemia and potassium loss during maintenance digoxin therapy. <i>Br Heart J</i>. 1976;38(2):167-172. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1259829\">[PubMed 1259829]</a></p>\n<p>3. Jorgensen AW, Sorensen OH. Digitalis intoxication. A comparative study on the incidence of digitalis intoxication during the periods 1950-52 and 1964-66. <i>Acta Med Scand</i>. 1970;188(3):179-183. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5526940\">[PubMed 5526940]</a></p>\n<p>4. Rodensky PL, Wasserman F. Observations on digitalis intoxication. <i>Arch Intern Med</i>. 1961;108:171-188. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13742523\">[PubMed 13742523]</a></p>\n<p>5. Beller GA, Hood WB Jr, Smith TW, Abelmann WH, Wacker WE. Correlation of serum magnesium levels and cardiac digitalis intoxication. <i>Am J Cardiol</i>. 1974;33(2):225-229. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4810019\">[PubMed 4810019]</a></p>\n<p>6. Sundar S, Burma DP, Vaish SK. Digoxin toxicity and electrolytes: a correlative study. <i>Acta Cardiol</i>. 1983;38(2):115-123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6603084\">[PubMed 6603084]</a></p>\n<p>7. Shapiro S, Slone D, Lewis GP, Jick H. The epidemiology of digoxin. A study in three Boston hospitals. <i>J Chronic Dis</i>. 1969;22(5):361-371. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5352781\">[PubMed 5352781]</a></p>\n<p>8. Wang MT, Su CY, Chan AL, Lian PW, Leu HB, Hsu YJ. Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study. <i>Br J Clin Pharmacol</i>. 2010;70(2):258-267. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653679\">[PubMed 20653679]</a></p>\n<p>9. Raja Rao MP, Panduranga P, Sulaiman K, Al-Jufaili M. Digoxin toxicity with normal digoxin and serum potassium levels: beware of magnesium, the hidden malefactor. <i>J Emerg Med</i>. 2013;45(2):e31-e34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23685098\">[PubMed 23685098]</a></p>\n<p>10. Gomez-Arnau J, Maseda J, Burgos R, et al. Cardiac arrest due to digitalis intoxication with normal serum digoxin levels: effects of hypokalemia. <i>Drug Intell Clin Pharm</i>. 1982;16(2):160-161. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7075468\">[PubMed 7075468]</a></p>\n<p>11. Ogilvie RI, Ruedy J. An educational program in digitalis therapy. <i>JAMA</i>. 1972;222(1):50-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5068673\">[PubMed 5068673]</a></p>\n<p>12. Beller GA, Smith TW, Abelmann WH, Haber E, Hood WB Jr. Digitalis intoxication. A prospective clinical study with serum level correlations. <i>N Engl J Med</i>. 1971;284(18):989-997. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5553483\">[PubMed 5553483]</a></p>\n<p>13. Myers MG. Diuretic therapy and ventricular arrhythmias in persons 65 years of age and older. <i>Am J Cardiol</i>. 1990;65(9):599-603. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1689934\">[PubMed 1689934]</a></p>\n<p>14. Brater DC, Morrelli HF. Digoxin toxicity in patients with normokalemic potassium depletion. <i>Clin Pharmacol Ther</i>. 1977;22(1):21-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=872493\">[PubMed 872493]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","3596":"<p><b>Title</b> Dofetilide / Verapamil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Verapamil may increase the serum concentration of Dofetilide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of dofetilide and verapamil. Dofetilide prescribing information lists this combination as contraindicated.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy male volunteers, the 4-hour AUC and peak plasma concentrations of dofetilide (0.5 mg twice daily) increased 26% and 43%, respectively, when coadministered with verapamil (80 mg three times daily) for 3 days.<sup>1</sup> There was no change in the dofetilide AUC over the entire dosing interval and a non-significant increase in the QTc interval of 6 msec was observed during combination therapy.<sup>1</sup><br><br>Dofetilide prescribing information states that peak plasma levels of dofetilide increased 42% when administered with verapamil.<sup>2</sup> There was also a higher incidence of torsades de pointes with this combination in an analysis of the supraventricular arrhythmia and Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) study patient populations.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but verapamil may increase hepatic and portal blood flow leading to increased dofetilide absorption,<sup>1</sup> inhibit the CYP3A4-mediated metabolism of dofetilide, or inhibit the cationic renal transporters responsible for the active renal tubular excretion of dofetilide.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Johnson BF, Cheng SL, Venitz J. Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. <i>J Clin Pharmacol</i>. 2001;41(11):1248-1256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11697758\">[PubMed 11697758]</a></p>\n<p>2. Tikosyn (dofetilide) [prescribing information]. New York, NY: Pfizer Labs; March 2016.</p>\n<p>3. Cho SK, Kim CO, Park ES, Chung JY. Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2014;78(6):1426-1432. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25060604\">[PubMed 25060604]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}